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SUMMARY
TYPE 2 DIABETES is a group of metabolic disorders that may resuit in a
procoagulant and thrombogenic predisposition, which is related to the arterial
complications. However it remains undetermined whether diabetic conditions may
affect deep vein thrombosis (DVI) and its resolution. The objectives of this study
were to determine the effect of diet-induced type 2 diabetes on the organization,
resolution and recanalization of venous thrombi, the inflammatory response, and the
fibrinolytic and MMP systems in a murine experimental model of venous stasis as
assessed by angiography and molecular techniques.
The resolution and recanalization of DVI was decreased in type 2 diabetic mice as
revealed by angiography, thrombus size and content and neovascular channel
(J quantification by immunohistochemistry. Recmitment of monocyte/macrophages,
detected by an anti-CD68 antibody, was ïncreased, and a higher coïlagen deposition
was found in the thrombosed inferior vena cava of diabetic mice. The plasminogen
activators, u-PA and t-PA were downregulated, and their inhibitor, PAl-1 was
upregulated conferring a relatively antifibrinolytic state in diabetic mice. The MMP
system was enhanced in diabetic mice at one week post DVI followed by a
decreased synthesis and activity at 2 weeks.
Diet-induced type 2 diabetes may impair the organization, resolution and
recanalization of DVI through increased inflammatoiy response and dismption of
fibrinolytic and MTvIP systems.
VSOMMAIRE
LE DIABÈTE DE TYPE 2 est un groupe de désordres métaboliques dont l’impact
est une atteinte artérielle, microvasculaire et macrovasculaire aboutissant à la
dysfonction endothéliale avec pour conséquences: inflammation, hypercoagulabilité
et thrombogénicité. Cependant, il n’est pas établi si ces désordres métaboliques ont la
même répercussion sur le système veineux et notamment sur les mécanismes de
l’organisation et la dissolution du thrombus veineux. Grâce à un modèle animal de
diabète de type 2 par consommation de diète riche en lipides et un modèle de stase
veineuse par ligature de la veine cave inférieure chez la souris, nous avons pu
déterminer les effets de ces désordres sur la résolution du thrombus veineux. Les
souris diabétiques présentent une diminution de la résolution et de la recanalisation
du thrombus veineux comme l’indiquent les résultats angiographiques, la taille du
thrombus et la quantification des néo-vaisseaux par immunohistochimie. La réponse
inflammatoire détectée au niveau de l’expression génique du CDL4 et par
immunolocalisation d’un marqueur des macrophages le CD68, est fortement activée,
accompagnée d’un dépôt de collagène au sein de la paroi veineuse. Le système
fibrinolytique est également atteint par une réduction de l’expression des ARNm et
des protéines des activateurs du plasminogène (u-PA et t-PA) et par une régulation à
la hausse du profil d’expression du PAT-l. L’expression des métalloprotéinases
MMP-2 et MMP-9 est temporellement affectée au cours de la thrombose veineuse.
Après une induction!activation du système à une semaine après formation du
thrombus, une réduction de la synthèse/activité est observée chez les animaux
diabétiques.
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Le diabète de type 2 induit par une diète enrichie chez la souris semble altérer
l’évolution du thrombus veineux à travers une réponse inflammatoire amplifiée, une
activité du système fibrinolytique diminuée couplée à un système des MJVWs activé
mais dont la modulation à la baisse semble durée-dépendante.
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1L INTRODUCTION
Li DIÂBETES MELLITUS
I. il Overview
Diabetes mellitus (DM) is a group of metabolic syndromes charactenzed by
chronic hyperglycemia, disturbances of carbohydrate, fat and protein metabolism
due to defects in ïnsulin secretion, insulin resistance or both (1, 2). Chronic
hyperglycemia is associated with multi-organ damage to the eyes, kidneys,
nerves, heart, and blood vessels (1). Cardiovascular disease is the leading cause
of premature death arnong patients with dïabetes. The new classification system
identifies four types of diabetes mellitus based on etiologv: type 1, type 2, “other
specific types” and gestational diabetes (1). The World Health Organization
(WHO) predicts that between 1997 and 2025, the number of persons affected
with diabetes vill double from 143 to approximatelv 330 million (3).
Type 2 is the most common form of diabetes mellitus. It is a metabolic disorder
that is primarily characterized by insulin resistance, relative insulin deficiency,
and hyperglycemia and lead to function impairment of many organs, most
importantly the cardiovascular system. Its prevalence is projected to rise in the
future (5). Approximately 90-95% of diabetes is ascnbed to Type 2 (4, 7), the
development of which is attributed to both polygenetic and environmental factors.
1.1.2 Cardiovascular complications and pathogenesis
Diabetes mellitus causes considerable morbiditv and mortality primarily due to
microvascular (retinopathy, nephropathy, vasculopathy) and macrovascular
2(ischemic heart disease, stroke, peripheral vascular disease) complications (6, 7),
which can lead to considerable disability and premature death. Cardiovascular
disease (CVD) is the major complication of type 2 diabetes and is responsible for
more than 50% and up to 80% of deaths in people with diabetes as well as for
substantial morbidity and loss ofquality of life (3).
Although the pathogenesis of CVD in diabetes is not vet fully underslood.
multiple metabolic and endocrinologic factors are implicated (6, 7).
Hyperglycemia and hypennsulinemia due to insulin resistance are two metabolic
abnormalities associated with type 2 diabetes mellitus and result in macrovascular
and microvascular complications in multiple organ systems which accounts for
the morbidity and mortalitv associated with this disease.
The phenotype associated with insulin resistance includes a dyslipidemia that is
characterized by increased very low-density lipoprotein triglyceride levels,
decreased high-density lipoprotein-cholesterol levels, and the presence of small,
triglyceride-enriched, low-density lipoproteins (6, 8, 9). Clinical trials have
shown that correcting the hyperglycemia can attenuate some of the microvascular
complications of diabetes, such as retinopathy and nephropathy, but cannot
suppress macrovascular complications, such as coronary heart disease (CITD) due
to atherosclerosis.
Oxidant stress and inflammation accelerate CHD by activating the
diacylglycerol-protein kinase C (DAG-PKC) signal transduction pathway,
possibly by enhanced formation of glycosvlated proteins and advanced glycation
products and/or by increasing endothelial dysftinction (8). Recent studies have
3shown possible biochemical mechanismsl by which hyperglycemia could cause
its adverse effects on the vascular cells (figure 1).
Insulin possesses anti-atherogenic properties. Insulin increases mtrous oxide
(NO) production, which can cause vasodilatation and retard the migration and
growth of arterial smooth muscle ceils under physiological conditions (7). In
pathological states of insulin-resistance, the enhancement of NO production from
either acute activation of nitric oxide synthase (NOS) or endothelial ceil NOS
(eNOS) by insulin are blunted (9). Moreover, hypennsulinemia may contnbute to
atherogenesis by stimulating the growth and production of the extracellular
matrix (ECM) (10).
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Figure 1: Four main pathways implicated in hyperglycemia-induced diabetic
microvascular disease. (The Maillard reaction and diabetes mellitus. Dr Alejandro
Gugliucci MD, PhD).
4Metabolic risk factors include dyslipidemia, hypertension, glucose intolerance,
and a prothrombotic state (11). The latter is a newly recognized factor in type 2
diabetes which rnanifests with increased fibrinogen levels, increased plasminogen
activator inhibitor-1 (PAF-l), and platelet abnormalities (12-14).
1.1. 3 Diabetes and risk of thrombosis
There are several ways in which diabetes predisposes to a higher risk of
thromboembolic events: alteration of the coagulopathic proteins, endothelial
dysfunction, increased platelet adhesions, and altered fibrinolysis.
Diabetes can cause changes in the haemostatic system including increased
concentration of fibrinogen, factor VII, von Willebrand factor (vWf), and
plasminogen activator inhibitor 1 (PAl-1) (15), as weII as decreased tissue
plasminogen activator (tPa), eNOS, and NO production (16). These changes may
resuit in endothelial dysfunction, increased adhesion of platelets and monocytes,
abnormal fibrinolysis and hypercoagulation, and form a prothrombotic state. We
will review them in details.
1.1.3.1 Endothelial dysfunction
Vascular endothelial ceils maintain their vascular integrity through the release of
a variety of paracrine factors such as NO, which regulates vasodilatation,
anticoagulation, leukocyte adhesion, smooth muscle proliferation and the
antioxidative capacity of endothelial cells (17). Endothelial dysfunction has been
detected in patients with diabetes and now is a well recognized phenomenon.
Hyperglycemia and insu]in resistance are thought to be the primary reason, as
5they change intracellular metabolism and produce excess superoxide radicais
inside vascular celis (1$, 19). In mm, these molecules impair release of NO,
increase NO destruction, eiihance release of endothelium-derived constricting
factors and decrease sensitivity of the vascular smooth muscle to NO through
mediators such as protem kinase C, the polyol pathway, non-enzymatic glycation
and oxidative stress (18). As a resuit, titis leads to an imbalance between smooth
muscle ceil growth, promotion and inhibition, thrombosis and fibrinolysis,
inflammation, and ceil adhesion (20).
L 1.3.2 Increased adhesion of platelets and monocytes
Platelets are small anucleate discoid ceils that circulate in the bloodstream and
participate in hemostasis and repair of vascular injmy (19). The abnormal
metabolic state that accompanies diabetes may activate platelets and alter their
functional properties. Activated platelets interact with the endothelium and
promote adhesion of platelets to monocytes (21). Many studies have
demonstrated that platelet degranulation further increases platelet activation and
diminishes the platelet’s sensitivïty to natural antiaggregating agents (21-23).
Circulating platelet-monocyte aggregates may release procoagulant, oxidative and
mitogenic factors (24). Ail these signiflcantly contnbute to the inflammatory and
procoagulant response in diabetes.
1.1.33 Abnonnai fibnnolysis and hypercoagulatîon
Defects in the coagulation and fibrinolytic cascade are important pathological
mechanisms that can lead to thrombus formation (25). In healthy conditions. the
endogenous flbnnolytic system represents an equilibnum between activators of
6plasminogen (primarily tPA) and inhibitors of these activators such as PAl-1 (26).
PAl-1 synthesis and release is regulated by insulin, promsulïn, VLDL cholesteroL
and various cytokines. In the diabetic condition, the equilibrium between
endogenous tissue plasminogen activator and PAl-1 is akered, as evidenced by
decreased levels oftP& increased tissue factor (TF) and PAl-1 (26). This is likely
assocïated with increased production of proinflammatory cytokines such as
interleukin (IL-6) from adipocytes. Etevated PAl-1 decreases local fibrinolysis
and promotes hypercoagulation (27). Raised concentrations of fibnnogen, von
Willebrand factor and other endothelium-denved mediators increase blood
viscosity and promote platelet activation and adhesion (21).
Some evidence shows that diabetes mellitus mav resuit in abnormal fibrinolysis
and hypercoagulation predisposing to a procoagulant state. However, it is not
known whether these abnormalities cause increased nsk of venous
thromboembolism and whether they affect thrombus recanalization. Data about
this remains controversial. A recent retrospective study showed that the nsk of
VTE among diabetic patients is significantly increased as compared with the
non-diabetic population (16).
In addition, diabetes may resuft in loss of balance in the production and the
degradation of ECM proteins like fibronectin and collagen may lead to structural
alterations such as basement membrane thickening and ECM protem deposition
(28, 29). It is not known whether these changes cause an increased risk of venous
thromboembolism.
7L1.4 Diabetic mouse models
Mouse models of type 2 diabetes are likely to be as complex and heterogeneous
as the human condition. Strains of mbred mice and mice that spontaneously
develop a type 2 diabetes-like phenotype through spontaneous mutations or
induced mutations (La, transgenic, targeted/”knockout”, or chemicallv induced
mutations) have been generated and are used in a wide variety of research areas
including cardiovascular biology, developmental biology, diabetes and obesity,
genetics, immunology, neurobio!ogy, and sensorineura! research (30, 31).
The genetically obese Zucker rat (32) is a spontaneous model of type 2 diabetes
that has a missense mutation in the leptin receptor gene (33, 34). Other examples
of spontaneous genetic mutations include the diabetic dbldb mouse that contains a
mutation in the leptin receptor gene (35) and the ob/ob mouse, a mode! for obesity
that Yacks the leptin protein (36). Genetically engineered models are now
becoming the forefront of animal researcft Another common way to develop a
type 2 diabetic mouse mode! is by diet induction. To establish tins model, an
appropnate diabetogenic diet should be given to C57BL/6 mice for 10 weeks to
induce obesity, hyperglycemia (with fasting blood glucose levels greater than 240
mgldl), insulin resistance (with b!ood insulin levels of greater than 150
microU/ml), and increased plasma cholesterol concentrations. Thus, tins model
displays ail the metabolic abnormaiities of the human condition: obesity,
hyperglycemia, and hypennsulinemia (37).
oo
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Genetic factors may determine susceptibility to diabetes even with a standard
high fat diet. Certain inbred mouse strains differ in their susceptibility to high fat
diet-induced diabetes (39, 40) with C57BL/6J mice showing susceptibility to the
weight gain and insulin resistance when feU with a high fat high sucrose
diabetogemc diet (30, 41) These and other observations show that profound
interactions between diet and genetic factors influence glucose homeostasis (38,
42, 43).
In this study, the C57BLI6J (B6) mouse stram vas chosen as a model for
studying diabetes mellitus, as this strain carnes a genetic predisposition to
develop non-msulin-Uependent (type 2) diabetes.
91.2 DEEP VENOUS THROMBOSIS
Deep venous thrombosis (DVT) is a blood dot that forms in a vein deep in the
body. Generally, most deep vein dots occur in the lower leg or thigh. They also
can occur in other parts of the body such as in the lungs, resulting in pulmonary
embohsm (PE). They have a high prevalence both in the community and in
hospitals, and are of considerable morbidity and mortality (44).
L2.1 Prevalence and nsk factors
DVT is a life-threatening and costly health problem (45). In young individuals,
the incidence of DVT is of 1/100,000 people; al middle age it is approximately
1/1000, which is also the overail incidence; thereafler, it increases steeply and
approaches 1 %/year (46). DVT tends to be asymptomatic for long periods of time
and difficuit to detect by clinical examination unless it reaches a threshold for
occlusion leading to symptoms or signs ofvenous insufficiency.
The pathogenesis of DVT invokes ‘Virchowts triad’ and is considered to be a
combination ofchanges in stasis of blood within the veins, ‘intimai injury’ in the
wall ofthe blood vessel, and ‘hypercoagulability’. It is a senous problem because
of its clinical sequelae including pulmonary embolism and chronic venous
insufficiency (postphlebitic leg pain, swelling, chromc venous stasis ulcers,
venous valvular incompetence, lipodennatosclerosis and claudication).
The formation of DVT is multifactorial. Many of the classic risk factors for
artenal thrombosis are also risk factors for venous thromboembolism (47).
Hereditaiy factors include gene mutations (such as factor V Leiden, the G2021 OA
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(E prothrombin) and deficiencies in physiologic coagulation inhibitors (such as
protein C, protem S its non-enzymatic cofactor, and antithrombin). In addition,
increased levels of plasma factor VIII, fibrinogen, factor IX, factor XI,
prothrombm, homocysteine, lupus anticoagulant, and antiphospholipid antibodies
mav also be implicated (48, 49). Acquired factors that can contribute to DVT
include smoking, hypertension, varicose veins, cardiac dysfimctions, obesity,
malignancy, hospitalization, surgery, venous trauma, immobilization, estrogen
therapy and pregnancy (50). Recently, a retrospective study showed that the nsk
of venous thromboembolism among diabetic patients is greater than in the
non-diabetic population (49). 11 is widely accepted that multiple nsk factors
interact which determines the nsk of thrombosis (51).
1.2.2 Nonnal venous anatomy
Understanding venous pathophysiology requires some knowledge about venous
anatomy and physiology. The primay function of the systemic veins is to retum
deoxygenated blood back to the nght side of the heart and to act as a blood
resenroir. Approximately 75% of the blood volume is contained within the
venous system.
Veins differ from arteries. Thev possess the same 3 layers as arteries but the
muscle layer is reduced. From the lumen to the penphery, the intima of the vein
wall is a thin layer of smooth muscle cells (SMCs) covered by the endothelium.
Undemeath the intima, the media by which the appearance of a mdimentary
internaI elastica separates both layers consists of a thin inner layer of
longitudinally oriented SMCs and a more prominent outer layer of
11
circular-onented SMCs. both embedded in an extracellular matrix. The adventitia
is composed of fibroblasts, bundies of collagen fibers, capillaries, and clusters of
longitudnmlly onented smooth muscle ceils (Figure 2).
The thin and collapsable venous wall allows variations in shape with minimal
changes in pressure (venous system is a low-pressure system) and is responsible
for the capacitance function of the venous circulation. Veins are normally only
partially fihled with blood. They have three times the cross-sectional area of
corresponding arteries.
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Figure 2: Vein wall with the intima underlying the endothelium, the media and
the adventitia Scale bar is 200 p.m (44).
Veins of the extremities have valves. These are thin delicate bicuspid structures
made of fibrous and elastic tissue lined with endothelium. At the site of each
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valve the vein is dilated creating a sinus space around the valve which facilitates
the opemng and closing ofthe valve. Few valves are located fi the femoral veins;
the vena cava and common iliac veins are valveless (52). Ttvo venous systems
exist in the upper and lower extremmes, the superficial and the deep venous
system which are connected by perforating veins. The major superficial veins of
the extremities have thicker walls than the deep veins. Under normal
circumstances, two ‘pumps’ (foot and caif pumps) work together to propel venous
flow against gravity and bicuspid valves direct flow from the superficial to the
deep system. The purpose of the valves is to break up the column of blood in the
vein and ensure unidirectional flow. Disease states interfere with these pumps
leading to venous stasis and thrombosis which compromises valve function and
resuits in venous hypertension (53).
In contrast to arterial thrombosis, which usually develops in association with
vascular-wall injuw leading to platelet-rich thrombus, venous thrombosis
develops in regions of disturbed flow and relative stasis (as obsened in the caif or
venous sinuses), ofien in association with increased coagulability or endothelial
damage. The thrombi are composed predominantly of fibnn and red blood celis
(54). Deep vein thrombosis may lead to residual venous obstruction or reflux and
resuh in post-thrombotic complications. Enhancing resolution of venous thrombi
may preserve valve integrity and reduce the incidence of post-thrombotic
complications (55).
L2.3 Resolution of thrombus
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DVT resolves by a the development of venous collaterals (vasculogenesis), dot
retraction, organization and recanalization (angiogenesis) that is similar to the
formation of granulation tissue in healing wounds (56). These processes may
occur simultaneously and are influenced by the fibrinolytic and matrix
metalloproteinases (MMPs) systems through a series of cellular and molecular
events (Figure 3) (57).
Cellular pathway
Thrombus Growth Factors
Cytoldnes
Molecular pathway
j uPa Ï
Figure 3: Cellular and molecular pathways during resolufion ofthrombus
9nhl ammatory ceils
•Endothelial ceils
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• Organization
• Resolution
• The fibrinolytic system
• MMPs and their inhibitors
• Extracellular matrix
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1.2.3.1 Cellular pathway
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(f The resolution of thrombus occurs through recruitment of inflammatoiy
(mainly monocytes), invasion of endothelial ceils (ECs), vascular smooth muscle
cells (VSMCs) and myofibroblasts leading to recanalïzation (5$). Several cellular
processes occur: (a) covering of the surface of thrombus with neutrophils,
monocytes (MCs) and an endothelial layer; (b) penetraflon by neutrophils and
monocytic ceils; (e) development of myofibroblasts and new capillaries; and (cl)
recanalization—the formation of one or more channels inside and parallel to the
original vesset (59).
1.2.3.1.1 Inflammatozy cel]s
Thrombus formation and its resolution are both strongly associated with a
subacute inflammatory reaction (60) with the release of fibrinolvtic, chemotactic
(J’ and growth mediators. Early afler venous thrombosis, circulating
migrate through the vein wall, possibly via the vasa vasora and respond to
chemokines by invading the thrombus, which causes thrombus retraction and
lysis. Subsequently, monocytes, macrophages and lymphocytes are the
predominant leukocyte subpopulations which promote tissue remodeling,
recanalization and also retraction of the thrombus (61, 62).
The thrombus contains trapped thrombm and fibnn that are potent monocyte
chemoattractants (17). The process of recanalization of thrombus is based on the
abilitv of MCs/Mphs (monocytes/macrophages) to penetrate the extracellular
matrices and create tubular spaces (“tunnels”) of lower density (60, 63).
Recanalization is induced by expression of a variety of cytokines, angiogenic
factors, proteases and their inhibitors that regulate cell migration, extracellular
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mati-ix turnover and tissue remodeling (4, 6, 24, 25). It is also plausible, however,
that once monocytes convert to the macrophage phenotype in the thrombus, their
fibnnolytic activity increases. which causes lysis of the thrombus (64). Currently,
proteolytic activity of MC5/Mphs on vasculogenesis based on the engraftment of
circulating EPCs is thought as an important mechanism of recanalization of
thrombus (59, 60).
Whether the inflammatoiy response after DVT is affected by hyperglycenna
remains to be determined.
1.23.1.2 Endothelial ceils
As a unique multifunctional ceil with cntical basai and inducible metabolic and
synthefic functions, ECs may react to physical and chemical stimuli within the
circulation and regulate haemostasis, vascular remodeling, vasomotor tone, and
immune and inflammatoiy responses. In addition, ECs play a pivotai i-ole in
angiogenesis and vasculogenesis (65, 66). Endothelium in resting state is both an
anticoagulant and antithrombotic by secretion of a variety of molecules important
for the regulation ofblood coagulation and platelet function, such as mtric oxide,
prostacyclin and thrombomodulin. Vessel exposure to cytokines or
proinflammatoiy molecules may shifi the balance towards a
procoagulantlprothrombotic phenotype of the ECs (Figure 4) (65) and inhibit
fibnnolysis by reducing the component of the fibnnolytic system. The balance of
endothelial properties can be tipped to favor platelet aggregation and dot
formation (67, 68). Operating in coordination, these changes can allow fibnn
formation and platelet activation.
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Figure 4: Schematic representation of the role played by endothelial ceils in
coagulation and fibrinolysis pathways. NO, nitric oxide; PAF, platelet activating
factor; PGI2, prostacyclin; tPa, tissue plasminogen activator; TXA2, thromboxane
A2; UK, urokinase; vWF, von Willebrand factor; WPb, Weibel-Palade body (65).
Moreover, ECs coordmate the recruitment of inflammatorv celis to sites of
thrombus. These celis produce and release cytokines and growth factors serving
as communication signais to leukocytes. Cytokines induce a promflammatoiy
phenotype of endothelial ceils. Upon activation of these ceils with tumor necrosis
factor- a (TNF-Œ) or mterleukin-1 (IL-1), platelet-activating factor (PAF) is
secreted and stimulates platelet aggregation and neutrophil adhesion to regulate
vascular remodeling (69).
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(E Recanalization of thrombus is similar to angiogenesis, because
may be conceived as the formation of endothelialized channels lined by
“endothelial-like” celis, which express many of the endothelial markers (e.g.
CD3I, VCAM-1 and ICAM-1) (70). Recanalization is also marked by new
formation of vessels which stain for laminin, a basement membrane protein that is
known to promote early EC migration and capillary tubule formation within the
organizing thrombus. vWF, thrombomoduÏin and tissue factor are expressed in
the larger, more prominent channels that appear in older thrombi suggesting that
they are lined by more mature ECs (71). This process requires different sequential
steps including the release of proteases from activated ECs with subsequent
degradation of the basement membrane, ECs migration, proliferation, and
differentiation of mature blood vessels into the interstitial space (69, 72).
Some studies performed in our Iaboratoiy on cou embolization of intracranial
aneurysms showed that early endothelial invasion of the dot leads to
recanalization and recurrence of aneulysms. Moreover, this process can be
prevented by endothelial denudation (73), which may prove that the endothelium
plays an important role in recanalization offlwombus.
However, whether the process of recanalization and neovascularization of
venous thrombi is affected by type 2 diabetes is unknown.
L23.13 Myofihrob]asts
Myofibroblasts are highly specialized mesenchymal ceils derived from
fibroblasts. These ceils populate the adventitia tunica (74) and participate in
vesse! injury repair as well as thrombus recanalization. In the injured vessel,
1$
numerous cytokines and growth factors (i.e., TGf-) can influence the
proliferation level offibroblasts as well as their transition to myoflbroblasts (74).
Several unes of evidence indicate that uPA appears to be an important
determinant influencing adventitial ceil proliferation and myofibroblastic
modulation. In injured adventitia, exogenous uPA stimulated myofibroblast
proliferation and in vitro, upregulated the content of Œ-SM actin in fibroblastic
celi culture. Moreover, uPA neutralizing antibody attenuated a-SM actin
expression by adventitial ceils after injuiy of vesse! (75).
During organization and recanalization of thrombus, the balance between
uPA-dependent development of endothelialized channels and MTvW-9-dependent
contraction by myofibroblasts of the residual provisional fibrin/collagen matrix
between recanalized channels, would resuit in progressive enlargement of the
recanalized spaces (59).
123.1.4 Ptatelets
Platelets are ceil fragments released from the bone marrow into the bloodstream
and involved in the cellular mechanisms of pnmaly haemostasis. When a blood
vessel injury occurs, platelets exhibit a sequence of events: 1) adhesion of
platelets to the injury site, 2) spreading of adherent platelets over the exposed
subendothelial surface. 3) secretion of platelet granule constituents, 4) platelet
aggregation, and 5) platelet coagulant activity (22, 76). Endothelium disruption
provides binding sites for adhesive proteins such as von Willebrand factor (vWF)
in the subendothelial matnx (winch binds to the platelet g!ycoprotein Ib/IX
complex) and flbnnogen, as well as fibronectin through integrin receptors. These
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adhesive proteins are thought to form a bridge between platelets and
subendothelial connective tissue. Once they adhere to the subendothelium,
platelets spread out on the exposed surface and additional platelets from the
circulation adhere, first to the basal layer of adherent platelets and eventually to
one another. Fibnnogen mediates platelet aggregation to form a mass of
aggregated platelets through building bridges from platelet to platelet (22, 76).
Imtially, the platelets involved in the thrombus formation favour angiostatic
chemokines, such as platelet factor-4 and subsequently secrete angiogenic
cytokines such as vascular endothelial growth factor (VEGf) which complexes
with fibronectin resulting in ECs migration and proliferation. This complex is
more potent than VEGf alone (77) which may regulate the revascularization of
thrombus.
1.23.1.5 Progenitor cetls
Progenitor cells arise from division of stem cells. A subset of these cells such as
endothelial progenitor cells (EPCs), along with the properties of hemangioblasts
that express the leukocyte antigen, CD45 (78), have been implicated in
revascularization, vascular repair, and myocardial regeneration. In addition,
mesenchymal stem cells also can differentiate into both VSMCs and endothelial
celis, and reveal a high degree of plasticity to participate in the development of
vascular systems, including angiogenic sprouting and vessel enlargement (79, 80).
Recent reports suggest that following thrombus formation, circulating EPCs
denved from bone marrow stem celis may arrest at the site of thrombus, infiltrate
through thrombus, and differentiate into endothelial cells to contribute to
20
(E endothelialization/recanalization of thrombus, or into a-SMA positive ceils that
participate in neointima formation (81, 82). Their angiogenic effects are most
likely mediated by secretion of growth factors (82). Significant numbers of bone
marrow-derived progemtor ceils have also been found in naturally resolving
thrombus (59). As shown by Singh and coworkers, thrombus resolution is
markedly delayed in urokinase gene deleted animais which can be rescued by
bone marrow transplantation ($3).
L23.2 Moiecular patbway
The fibnnolytic system and matrix metalloproteinases (MMPs) are major
components of the molecular pathway and play a pleiotropic role in resolution of
thrombosis. The fibnnolytic system may regulate endotheiial ceii infiltration by
(E degrading fibnn matrices ($4). MMPs expressed by ECs, neutrophils,
monocytes/macrophages can degrade the extraceilular matrix to promote the
migration of ECs ($5). In addition, chemotactic agents and growth factors
(including angiogenic cytokines) expressed or secreted by inflammatoiy celis and
platelets also participate in the interaction of molecular and cellular pathways
(86). Ail ofthese may affect tissue remodeling and revascularisation ofthrombus.
1.2.3.2.1 The fibiïnolytic system and major components
The fibnnolytic system constitutes a critical response mechanism to thrombus
formation and evolution. The central components comprise an inactive
proenzyme, piasminogen that can be converted to the active enzyme, plasmin,
winch in tum degrades fibrin into soluble fibrin degradation products. Two
immunologically distinct physiologie plasminogen activators (PA) have been
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(Z identïfied: the tissue-type PA (tPa) and the urokinase type PA (uPa) together with
the major inhibitors of PA, plasminogen activator inhibitor-1 and -2 (PAl-1,
PAl-2), while plasmin is inhibited mainly by Œ2-antiplasmin. tPa, a serine
protease, is responsible for the removal of fibnn from the vascular tree (87, $8),
whereas, uPa bound to its receptor uPAR, is regarded as the critical trigger for
plasmin generation dunng celi migration and invasion, and may be responsible
for regulating the activation of other proteases, such as the MMPs (eg,
procollagenases and macrophage elastase) (figure 5) ($8). Plasmin can also
activate or liberate growth factors from the ECM including latent TGf-131, bfGF
and VEGf (89).
PAl-1. a member of the serine proteinase inhibitor ($ERPIN) family is the
pnmaly inhibitor of plasminogen activators in plasma and in the pencellular
matrices, which bonds two-chain active uPA or tPA to reduce actîvity of uPA or
tPA through covalent complex formation ($8). Vitronectin (VN) binds to uPAR,
an abundant plasma and matrix glycoprotein; whereas PAl-1 controls recognition
of VN by uPAR or the Œv133 integrin receptor, and is stabilized by binding to a
plasminogen activator inhibitor binding protein identified as S-protein, suggesting
a role in coordinating ceil adhesion and migration (90). Moreover, PAl-1
detaches celis from exïracellular matrices; vitronectin, fibronectin and type I
collagen through an uPA’uPAR-dependent mechanism by inactivating integrins
(91). Thus, PAl-1 could be considered as a deadhesion molecule (e.g.,
thrombospondin, tenasin) disrupting the link between the cytoskeleton and the
focal adhesion plaque and resulting in the loss of stress fibers and a decrease in
the strength of integrin—ligand interactions (182).
22
C
G
Dunng natural resolution of venous thrombi, there is an increase in the activity of
the fibnnolytic mediators, tissue-type plasminogen actîvator (Wa) and
urokinase-type plasminogen activator (uPa) and this activity is expressed by
invading monocytes (182)
PAl-1
•ECM degradalion
•achvation of TGF-3
Figure 5: M extensive network of additional proteases, inhibitors, receptors and
modulators are directly associated with and are influenced by the PA system. The
largest group is the mati-ix metalloprotemases (MMPs) and their respective
inhibitors, the tissue inhibitors ofMMPs (TIMP$) (94).
The levels of uPA were usuaÏly found to be greater than those of tPa Subsequent
gene knockout studies have shown that deletion of the gene encoding for uPA
markedly inhibited normal thrombus resolution, but the tPa gene knockout had no
effect. Absence of uPA is also associated with delayed monocyte recruitment into
the thrombus (83).
uPA
plasmin
proMMP activatian, active MMP
proMMP
actîve MMP
MT-MMP
ECM
breakdown
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uPa rnav have a dual function; one related to proteolytic matrix breakdown, the
other related to matrix production via proteolytic activation of growth factors,
such as the fibrogenic TGf-Bl. This dual role of uPa may explain why ECM
degradation and collagen deposition were both aftenuated in the absence of uPa
(95).
PAl- 1 plays a determining role in controlling thrornbus formation. PAl- 1 activity
was increased in patients with deep vein thrombosis (DVT) and pulmonary
embolism (96). further evidence for the role of PAl-1 in venous thrombosis
cornes from animal models. Transgenic mice, that were geneticaÏly engineered to
synthesize PAl- 1 in excess, had higher rates of venous thrombosis than mice with
normal PAl-l levels (97). In a mode! of venous stasis-induced DVT afler ligation
of the inferior vena cava, Deatnck and coworkers demonstrated an alteration in
the normal profibrinolytic to antifibnno!ytic state of the vessel by a decrease in
the ratio ofuPA to PAl-1 (60).
Clinical and expenrnental studies have suggested an irnportant role of PAl- 1 in
artenal and venous thrombosis and the maintenance of systemc vas cu!ar
hemostasis (98). Moreover, expenments with transgenic mice deficient in PAl- 1
support a role for this serpïn in both vascular remodeling afier arteria! injuiy (99)
and the formation of puÏmonaiy fibrosis that occurs afier inflammatory injury
(100). upregulation of PAl-1 in endothelial ceils and smooth muscle cells after
acute vesse! injuiy (lOi) and thrornbus formation (102) suggest that elevated
PAl-1 may play a role in vascular remodeling afler deposition of a
thromboembo!us.
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There is increasing evidence that diabetes mellitus is associated with several
defects in coagulation and fibrinolysis that may Iead to a procoagulant,
thrombogenic predisposition (103). However, it is flot known whether these
perturbations cause a decrease in thrombus recanalization.
1.2.3.2.2 Matnx metatioproteinases and their inhibitors
Matnx metalloprotemases (MMPs) are a family of zinc-dependent
endopeptidases, which can degrade essentially ail ECM components in
physiological and pathological conditions, but also parficipate in celi migration,
angiogenesis, and tissue remodeling dunng organ development, wound healing,
inflammation, and cancer (104, 105, 106). Currently more than 24 members ofthe
MMP family have been identified and classified into subgroups of collagenases,
gelatinases, stromelysins, and membrane types (MT-MMPs) based on their
structure and substrate specificity (107, 10$). MI’Ws are produced by secretion of
both vascular and inflammatory celis. Their activity is regulated at multiple
levels: gene transcription and synthesis of inactive zymogens, posttranslational
activation of zymogens, and interactions of secreted MMPs with tissue inhibitors
of metalloproteinases (TIMPs) (104, 105). The TIMP family known at present
consists of four distinct members (TIMPs 1 to 4), and is expressed in most tissues
and body fluids. Except for TIMP-dependent inhibition of MMPs, these
proteinases have been recently recognized to stimulate ceil proliferation
participating in mitosis and tissue differentiation, to regulate ceÏl survival and
apoptosis, and to inhibit angiogenesis (105). The balance of MMPs and TIMPs
activity controls the diffusion of substances and the migration of ceils through
ECM. These proteinases also modulate signal transduction pathways by various
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substrates, mcluding inflammatorv mediators, growlh factors, and growth factor
receptors (105).
MMP-2 ami MMP-9 (gelatinases A and B) are the main enzymes able to degrade
non natural ECM gelatin and type IV collagen (109), which is the major structural
protein of the ECM. but also an ïntegral part of endothelium basement
membranes. ECM degradation and basement membrane disruption are the key
steps in thrombus organizatïon and recanalization. These enzymes play a cntical
role in vascular remodeling induced by altered arterial flow (110, 111), tissue
ischemia and aortic aneurysms (112). Moreover, MMP-2 activity is cntical for
migration of endothelial cells (113) and monocytes/macrophages (114). Targeted
deletion of MMP-2 abolishes angiogenesis in vivo (115, 116). Thrombin
treatment of endothelial celis induces MMP-2 activity (117) and pro-MMP-2 can
also be proteolytically activated in vitro by the coagulation proteins activated
proteinC (APC) (11$) and factorXa(119).
During expenmental venous thrombosis, the expression of MMP-2 and
MMP-9 is increased (60, 120). But their invo]vement in thrombus resolution
and vein walI fibrosis in diet—induced type 2 diabetic mice remains
undefined.
1.23.23 Extracellular matrix
The thin extracellular matnx (ECM) underlying the endothelium is termed the
basement membrane. It is made up of structural interacting glycoproteins
produced by VSMCs and fibroblasts (121). The most abundant components are
laminin, entactin, collagen W and glycosaminoglycans (heparan sulfate) (122).
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These ECM components act as structural support promotmg celi adhesion and
barners between tissue compartments regulating cellular migration. Basement
membrane components contain the RGD (arg-gly-asp) sequence that control ceil
shape, migration, proliferation, differentiation, morphogenesis, and survival
(123). Celis use a series of receptors (integrins, celi surface proteoglycans, and a
newly described class of cell-surface-expressed tyrosine kinase receptors) to form
linkages with ECM. In this cellular behavior, celis can be provided with
directional guidance dues for migration (124). When blood vesse! is damaged or
presents a platelet-fibnn thrombus, the ECM may act as a ligand to adhere to in
areas of exposed basement membrane on the endothelial monolayer by circulating
blood celis and neointimal ceils (123). The phenomena of the ceil-matrix
interaction can be modulated by the balance of activity of a class of proteases
known as MMPs and their inhibitors.
Thrombosis and inflammation that occur in DVI resuit in valve destruction and
chronic vein wall changes that lead to venous reflux and the syndrome ofchronic
venous insufficiency marked by thickened, noncompliant vein walls and
incompetent valves.
Afler the development of a DVT, a late fibrotic response, similar to a healing
wound, occurs in vein walls (60), involving the progression of the normally thin
and compliant vein wall to a relatively thick and fibrotic state. There is
deposition and accumulation of collagen procollagen I and procollagen III, and
loss of normal vessel ECM such as heparin su!phate which has antifibrotic
properties and is important for mediating norma! vessel phvsiologic responses
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dcposition and accumulation of collagen procoltagen I and procollagen Iii, and
!oss of normal vessel ECM such as heparin suiphate which bas antifibrotic
properties and is important for mediating normal vesse! physiologic responses
(125). Extracellular matrix molecules such as fibronectin and vitronectin enhance
endothelial cet! migration and tubute formation by binding to uv33 (126).
The presence of these molecules has yet to be confirmed in naturally
resolving thrombi, and moreover in hyperglycaemic conditions, but it seems
)ikely that they have a role in this process.
1.2.3.2.4 Selectins
The selectins are a small family of lectin-like adhesion receptors. There are three
fami)y members, L-, E-, and P-selectin. Their major physiotogicat rote is thought
to be largety responsibte for the initial attachment and rolling of leukocytes on
stirnulated vascular endothetium. Ibis family consists of P-selectin expressed on
activated platelets and activated endothelium, E-selectin expressed on activated
vascular endothelium, and L-selectin expressed on the surface of neutrophils.
P-selectin is present in the granules of platelets and the Weibel—Palade bodies of
ECs. It is first translocated to the plasma membrane of these ceils, mediating the
initial inflammatory response (127, 128). P-selectin plays a rote in perithrombotic
inflammation and in mediating leukocyte influx into areas of inflammation.
Previous studies have shown that decreases in thrombogenesis and increases in
thrombolysis can be achieved in primate, porcine, and rat modets of arterial and
venous thrombosis in which P-selectin is antagonized (5$, 129, 130). These
P-selectin driven interactions tead to activation of the coagulation cascade withC
2$
leukocyte tissue factor (TF) upregulation, which further potentiates vein wafl
inflammatory events.
1.2.3.2.5 Proangiogenic factors
Monocytes express a variety of proangiogenic factors such as VEGF, bfGF and
interleukin-$ (IL-8), a prototypic cysteine-X-cysteine (CXC) chemokine with
polymorphonuclear neutrophil (PMN)-activating and chemoattractant properties,
and confers proangiogenic activity (134), which may generate an ‘angiogenic
drive’ within the thrombus (65, 135). Both VEGF and bFGF are expressed in
resolving thrombi, and are associated with the appearance of channels within and
around the thrombus (136). VEGE expression was localized to several ceils in the
thrornbus, including endothelial celis and the monocyte infiltrate. Expression of
bFGF was found on mononuclear celis ami spindle-shaped ceils within the
thrombus (136).
Monocyte chemotactic protein-1 (MCP-Ï) is a potent and specific activator of
monocytes and basophils. In a rat mode! of venons thrornbosis, the vein wall
adjacent to the thrombus was found to contain increasing amounts ofMCP-1 and
when this cytokine is directfy injected into venous thrombus, it alters its
organization (137). Part of the effect produced by injecting MCP-1 may have
been as a consequence oC its angiogenic properties (Table 1).
o
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VEGF EC chemotaxis (135)
t EC mitosis
Mobilize EPC’s
bfGf EC mitosis (135)
t EC migration
t ŒV33 integrin
MCPI t EC chemotaxis (54)
t_capillary_sprouting
IL$ t EC chemotaxis (58, 65)
t EC mitosis
MMP2 t EC migration (6)
MMP9
*These are gencratly known proangiogenic activities associated with these factors
Table 1: Proangiogenic factors expressed within resolving thrornbus (70).
1.2.4 Treatment of deep vein thrombosis
Treatment costs to the U.S. health care system are in the range of billions of
dollars per year just for the acute treatment of venous thrombosis, without even
considering the arnount of rnoney spent on the treatrnent of the sequelae of DVT
(chronic venous insufficiency) and PE (chronic pulmonary hypertension) (13$).
1.2.4.1 Standard treatments
Prophylaxis and treatment of DVT aim to prevent propagation of the fractured
thrombi as emboli leading to death from pulmonary embolism. Another goal is to
minimize the sequetae of CVI known as the post-thrombotic syndrome. Enhanced
Factor ProAngÏogenÏcActivity* Reference
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thrombus resolution is associated with reduced valvutar damage and venous
hypertension and fewer long term complications (6, 139). Standard treatments
include anticoagulants (low-rnolecular-weight heparin that acts on both thrombin
and factor Xa or warfarin), thrombolytics agents (for example, streptokinase,
recombinant urokinase and tissue-plasminogen activator that lyse the thrornbi),
surgical thrombectomy and compression stockings as prophylactic measures.
These agents are often considered alternatives by inhibiting thrombus extension
and do flot accelerate natural thrombus resolution. Thrombolytics are less used
because ofa small but significant risk of severe hemorrhage (140) and in patients
with stroke or with a recent operation (6, 139, 140). Compression stockings are
sornetimes recommended to relieve pain and swelling, (141). However, these
treatments do not seem to effectively reduce the incidence ofthe post-thrombotic
venons insufficiency (142, 143).
1.2.4.2 New approaches
AÏthough acute therapy for DVT is well established, potential new therapies have
emerged to promote thrombus vascularization and resolution without altering the
normal hemostatic mechanisms, such as delivery of angiogenic growth factors
and cell-based therapy. The application of these methods may enhance rapid
resolution ofDVT, but also provide other perspectives on treatment.
1.2.4.3 Angiogenic therapy
A number of pro-angiogenic factors, including VEGF, IL-X, bfGf, have been
reported to enhance neovascularization of ischemic tissues (6, 61). Currentty the
concept of stimulating therapeutic angiogenesis has also been applîed to the
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recanalization of venous thrombus (Table 2). Treatment with recombinant iL-8 in
a rat model of JVC thrombosis resulted in increased recruitment of neutrophils,
monocytes and markedly promoted early neovascularization enhancing the
resolution ofthrombosis (61).
Varma and coworkers (144) used therapeutic administration of pro-angiogenic
compounds promoting DVI neovascularization, such as interferon inducible
protein (IP-1O), an angiostatic chemokine, basic (bFGF), a pro-angiogenic factor
and epithelial neutrophil activating protein (ENA-78), a pro-angiogenic cytokine.
These angiogenic chemokines increase thrombus neovascularization, but this
does flot correlate with smaller or less fibrotic DVT. Mechanisms other than
neovascularization may be more important to hasten DVI dissolution. VEGf
administration (136) enhance thrombus resolution by a variety ofrnechanisms (6).
VEGf, bFGf, platelet derived growth factor (PDGfs), placental growth factor
(PIGF), the angiopoietins and their receptors, which are mediators associated with
angiogenesis, have also been provcd to promote the formation of blood vessel
function (145, 146). These factors could provide more choice in treatment of
thrombosis.
1.2.4.4 Cell-based approach
Thrombus resolution depends on the interaction of an assortment of cells. Bone
rnarrow-derived progenitor cells are known to participate in revascularization,
provide the necessary precursors as these immature ceils can differentiate into a
diversity of phenotypes, including macrophage, lymphocyte and endothelial celis
(147). Recent studies have shown that thrombus resolution is markedly detayed in
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uPA knock out animais, but rescucd by bone rnarrow transplantation ($3). These
progenitor celis have been made to improve thrombus resolution as a celI-based
approach and showed some benefit in small clinical trials (147-149). Endothelial
progenitor celis, delivered Iocaily or injected into the circulation, incorporate into
newly formed vessels to enhance Local angiogenesis by secreting a variety of
pro-angiogenic cytokines (150).
Modulation of monocyte fibrinolytic and growth factor production in vitro, with
subsequent reinjection of these ceits, may provide an alternative treatment for
venous thrombosis. This therapy might also be useful to recanalize mature
thrombi when fibrinolytic treatment is ineffective (]5 1).
1.2.4.5 Gene therapies
Gene therapy is the insertion ofgenes into an individuals celis and tissues to treat
a disease. Endothelial progenitor cells are also used as vectors to deliver
pro-angiogenic genes. It bas been conflrmed that transplantation of endothelial
progenitor cells transfected with VEGf are more effective than unrnodifled cells
in the angiogenesis and revascularization of ischcmic tissues (152, 153). However,
this therapy is limited by vector toxicity. Current studies of gene therapy focus on
reducing toxicity and improving vectors by looking into mechanisms retargeting
vector to the tissue of interest, minirnizing or eliminating viral gene expression
(Table 2) (135).
o
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1L8 t neovascularisation, t blood tlow (61)
distal venous pressure, î resolution
VEGf î neovascularisation, î MO recruitmenL (88)
t organization, t LPA/uPA,
t_EPC mobilisation
bFGf t neovascularisation, î blood flow (56)
MuItpJe chemokines
VEGF isoforms lOOx more potent angiogenic etïect in (102)(121/165/189) ischaemic tissue
VEGF + PIGF Robust neovascularisation (101, 103)
Ccii based
EPCs ]ncorporate into neovessels, secrete (107,110, 1 11)
proangiogenic cytokines, known benefïts
in ischaemic tissue
Pluripotent stem Supply progenitors for multiple celi types (74, 107, 112)cells/bone marrow (Monocyte, lymphocyte, endothelial) into thromb s
o
Table 2: Potential new therapies promoting recanalization and resolution of
venous thrombi (6).
1.2.5 Treatment of complication
Proangiogenic therapy can cause complications such as inflammation with an
immunogenic response to viral vectors (154). Stimulation of therapy to
angiogenesis may resuit in rupture of atherosclerotic plaques, development and
growth of vascular malformations (155). Enhanced angiogenesis therapy atso
carnes risks of neoplasia and tumour growth. In addition, administration of bone
Therapy
Single chemokines
Actions inThrombus Reference
EPC as veCtor (EPC
+Ad.angiogenic I
gene construct)
More effective than EPC alone, greater celi
longevity
(113,115)
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marrow ceils can carry a theoretical possibility for malignant transformation. The
selection of single types of stem ceil may reduce treatment complication (6, 155).
1.2.6 Animal models ofvenous thrombosis
If an optimal animal model exists, it would have a natural propensity for venous
thrombosis, a similar clotting cascade and platelet interaction to that ofthe human,
a Iower extremity that cÏosely resembles the human with a functional caif
musculature, ability to walk upright and sufflciently tau (when standing) to allow
hemodynamic study and sufficiently large to allow surgical intervention (164).
Overali, large animais like pigs and monkeys have been better suited to study
thrombosis as they are more similar to human physiology than smaller species
such as mice, rats, rabbits and dogs (39). However, the study ofthrombosis with
these animais is restricted by cost and ethical considerations. Nevertheless,
numerous studies have used rodent models taking advantage of low cost,
availability, practical breeding, technical feasibility and the availability of
transgenic knockout mice. Some limitations may limit extrapolation to human
thrombi as the relatively rapid (3-4 weeks) rate of thrombus resolution in rodent
moUds and the difference in hemodynamics in the smaller diameter of the vena
cava may affect thrombus revascularisation (6).
Murine in vivo models are appealing because of their well-defined genetic
background, and the possibiiity of using syngeneic “knockout” and mutant mice
producing a variety ofmetabolicsettings.
Animal modeis of venous thrombosis have been classified as non-genetic and
genetic modeis. Non-genetic models of thrombosis have been produced by a
35
combination of blood-flow stasis with either increased coagulability or
endothelial damage (46).
Several injury models applied to the arterial systems have also been used in the
venous system. injection ofendotoxin (156), collagen and cpinephrine, factor Xa,
or tissue factor (157), thrombin (158) as well as hyperoxia (159) or hypoxia (160)
ail served to induce a hypercoagulable state and fibrin deposition in the mouse.
Other methods included application of 70 % ferric chioride (161), or sodium
morrhuate or long-term nitTic oxide synthase inhibition using L-NAME (162). In
addition, thrombosis can be induced using 1251-labeled fibrinogen mixed with
thromboplastin (163) After administration of the thrombogenic stimulus
systemically or directly into the stasis region, this mode! can be performed with
or without mechanical vena cava stasis (2). They include vein ligation (164), orC vein interruption by means of a silicone band or an intralurninal balloon catheter
(165), or by the intra-stent stenosis (166). f low stasis was also induced by a
combination of devascularization, electric injury (167), or photochemical injury
(23). These models represent useful tools for the better understanding of the
venous thromboembolic events under conditions similar to those seen in humans
(54). Other genetic models (such as transgenic models of thrombosis) are a
number of spontaneous or genetically engineered mouse strains with
overexpression or deletion of various elements in the lipid transporters,
coagulation, platelet, and fibrinolysis pathways.
As our objectives are focused on the pathogenesis of venous thrombosis in
diabetic mice, we used a reproducible model of venous thrombosis (168). The
inferior vena cava (IVC) stenosis model, with a 94.4% ± 0.5% reduction in IVC
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diameter (38), leading to a stasis-induced venous thrombosis is more adapted to
our goals, as shown by earlier studies that venous thrombi produced in this model
were forrned in flowing blood and were morphologically similar to human
thrombi (151). Moreover, this model bas more availability, improved technical
feasibility, standardization of local thrombosis and lower maintenance costs (169).
Thus, the ability to study thrombus recanalization in diabetic mice should be
appropriate in this model.
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C’ II RESEARCH
There is increasing evidence that cardiovascular complications in type 2 diabetes
mellitus can, in part, be explained by several defects of coagulation and
fibrinolysis (47), promoting adhesion of platelets and monocytes, and endotheliat
dysfunction increasing the risk ofthrombosis and vascular damage (170).
Venous thrombosis develops in regions of dïsturbed flow and relative stasis often
in association with increased coagulability or endothelial damage which should
predispose diabetic subjects to development of venous thrombosis.
(47). Recently, a retrospective study showed that a higher incidence of VTE i.e.
deep vein thrombosis (DVT) and pulmonay embolism (PE) was associated with
diabetes (47) and obesity, independent of age, race and sex. (171).
Furthennore. the concept that thromboembolic arterial diseases and VTE are two
distinct entities has been revised with numerous case control studies
demonstrating the potential link between venous and artenal thrombosis (172).
These finding led us to speculate that thrombus organization and resolution are
affected by the metabolic perturbations that arise in association with type 2
diabetes, such as hyperglycemia, insulin resistance, and increased release of free
fatty acids that engender a cascade of endothehum-mediated dysfimctions that
potentiate inflammation, abnormal fibrinolysis and thrombosis (7, 38, 47).
Because the majority of patients with type 2 diabetes have diet induced obesity,
we sought to study the effects of diabetes on venons disease using an
experimental modal of DVT in a mouse model of diet induced obesity/diabetes.
3$
(Z In this diabetic model, endothelial dysfunction and hypercoagulation have been
confinned (12).
11. 1. HYPOTHESES
Our hypotheses are that diet-induced type 2 diabetes will:
1) Impair venous thrombi resolution and recanalization.
2) Affect monocyte/macrophage recruitment in venous thrombi by activating
the inflammatory response which would be expected to enhance thrombus
resolution as reported by numerous studies in normal mice.
3) Resuh in prolonged exposure of vein wall to thrombus which allows vein
wall remodeling through ECM deposition.
C
4) Downregulate the molecular factors involved in the regulation of
fibrinolysis: the fibnnolytic system, especially uPa, the main protease
implicated in thrombus resolution.
5) Affect the plasminogen activators, the MMP system, particularly MMP-2
and MMP-9 will be enhanced.
11.2. RESEARCH GOALS
11. 2. 1. Main objective
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The aim of the study was to determine whether the metabolic perturbations that
characterïze type 2 diabetes mduced in fat diet fed mice would impair thrombus
organization, resolution and recanalization in an expenmental mouse model of
DVT using angiography analysis and molecular techniques.
11. 2. 2. Specific objectives
Many specific objectives arise from the main objective to achieve this research
project (summaiy in Table 3).
1) The first goal was to assess thrombus resolution and recanalization to see
whether type 2 diabetes alters angiographic and angiogenic responses
through analysis of angiographic scores, thrombus size and weight. and
neovascular channels detected by immunohistochemistr.
o
2) Second. to confirm the elevated inflammatoiy response through the
examination of the involvement of the monocytelmacrophage recmitment
in diabetes-related impairment of resolutïon in vivo by
immunohistochemistry.
3) Additional goal includes insight into the fibrotic response to evaluate
whether diet-induced type 2 diabetes mediates vein wall damage by
companng ECM deposition in thrombosed WC sections from normo- and
hyperglycemic mice.
4) Venous thrombolysis in vivo is mediated pnmarily by activation of the
plasminogen-plasmin axis. We thus examined the relation of the
fibrinolytic system to DVI resolution in high fat diet mice, through the
quantification of the mRNA and protein levels of the plasminogen
activators, uPa and tPa and their major inhibitor. PAl-1.
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5) Finally, we ïnvestigated MIvIP-2 and MMP-9 gene and protein expression
and their gelatinolytic activities in IVC/thrombus specimens obtained
from control and diabetic mice and their immunolocalization and
expression in IVC/thrombus sections.
Experimental design
10 week-diet-induced type 2 diabetes
Inferior vena cava thrombosis model
1 week 2 weeks
I - Thrombus resolution a) Angiographie score
RecanahzationlNeovascularization b) Thrombus area and mass
c) Neovascular channel quantification
a) CD 14 gene expression
t II - Inflammation b) Immunohistochenucal stammg
III - Fibrosis Picrosirius red staining
a) Gene expression (RT-PCR)
IV - Fibrmolytic system (uPA, tPA and PAl-1) b) Protem expression (Western blolling,
MMP system (MMP-2 and MMP-9) zymography and immunohistochemistry)
Table 3: Summary of specific objectives
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III. MATERIAL AND METHODS
Ail experimental procedures were approved by the institutional animal care
committee in accordance with guidelines of the Canadian Council on Animal
Care.
111.1 Diet-induced type 2 diabetic mouse models
The C57BL!6 mouse strain was used as a model of diet-induced type 2 diabetes.
Only male mice were used to avoid the potentially confounding effects of sex.
The C57BL/6 strain was chosen as it has provided the background for previous
experiments (173) and has the availability of various genetic knockouts. forty
mice, 5 weeks of age, purchased from Charles River (St-Constant, Quebec) were
maintained in a temperature-controlled barrier facility with a 12-hour light/dark
cycle and were given free access to food and water. Mice were fed rodent chow
pellets for a 1-week acclimatation period prior to initiation ofdiet studies.
Thereafter, the mice, 20 per group, were assigned to I of 2 dietary treatments for
10 weeks: the Iow-fat diet D12450B (control group) and the high-fat diet D12451
(diabetes group) fed ad libitum. D12450B (10 kcal% fat)! D12451 (45 kcal% fat)
have been used widely to develop diet-induced type 2 diabetes mice. Furthermore
D12450B was also used as diet of control group (203). Research Diets (New
Brunswick, N]) manufactured the diets. The composition of the diets is listed in
Table 4.
Body weight and plasma glucose of each animal were measured weekly
throughout the study until age of 16 weeks. Blood was drawn afler an 8-hour fast
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via saphenous vein in non-anesthetized mice. Plasma glucose concentration was
determined with ONETOUCH Ultra (LifeScan, Inc.). A successful type 2 diabetic
C57BL/6J mouse was defined as having average fasting blood glucose levels of
greater than l2mmolIL (174).
Table 4: Composïtion of the diets (formulated by Research Diets, Inc.,)
Product# D12451 D12450B
gm% kcal% gm% kcal%
Protein 24 20 19.2 20
Carbohydrate 41 35 67.3 70
Fat 24 45 4.3 10
Total 100 100
kcallgm 4.73 3.85
Ingredient gm kcal
Casein. 80 Mesh 200 $00 200 $00
L-Cystine 3 12 3 12
Corn Starch 72.8 291 31.5 1260
Maltodextrin 10 100 400
Sucrose 172.8 691 350 1400
Cellulose. BW200 50 0 50 0
Soybean Oïl 25 225 25 225
Lard 177.5 159$ 20 180
Minerai Mix S10026 10 0 10 0
DiCalcium Phosphate 13 0 13 0
Calcium Carbonate 5.5 0 505 0
Potassium Citrate. I H20 16.5 0 16.5 0
Vitamin Mix V10001 10 40 10 40
Choline Bitartrate 2 0 2 0
FD&C Red Dye #40 0.05 0 0.05 0
Total $58.15 4057 1055.0 4057
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C.’ 111.2 Animal model ofvenous thrombogenesis: a mouse infetior vena cava
stasis model.
M established rodent mode! of DVT by a combmation of low flow and
endothelial damage was used to mduce the formation of venous thrombi in the
vena cava of normal and diet-ïnduced diabetic mice (Figure 6) (175). Mice were
anesthetized with isoflurane (Baxter Health care Ltd), and the inferior vena cava
vas exposed below the renal veins through a midiine laparotomy incision. The
intestines were retracted, and retropentoneal blunt dissection of the infrarenal
vena cava was performed to mobilize aS mm segment distal to the lefi rena! vein.
A 5-0 Prolene suture was p!aced alongside the vena cava. A severe stenosis was
produced in the vein by tying a 5-0 silk suture around the vena cava to inc!ude the
Prolene suture. The Prolene tvas then pulled out to allow blood to continue to
pass up the vein. A neurosurgical vascu!ar clip was app!ied to the dissected vena
cava for 15 seconds on 2 separate positions, 30 seconds at a time to induce
endothelial damage. The intestines were replaced, and the abdominal wall was
sutured. The animais were then allowed to recover from the anaesthesia. The
mice tolerated the procedure well and were recovered in the !aboratoiy before
being retumed to the anima! housing facility. All operative deaths occurred in the
immediate penoperative penod and were re!ated to anaesthetic administration. No
remote deaths secondarv to infection occurred, and the mice continued to feed
well and had access to water and chow.
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111.3 Angiography
Angiography was used to assess blood flow through thrombus recanalization. The
mice were sacrificed at 1 (DM n10, control n10) and 2 weeks (DM n10.
control n=10) afier angiography was performed. Mice were injected with lethal
dose of pentobarbital (Somnotol; MTC Pharmaceuticals, Cambridge, Ontario,
Canada) (65 mg/mL; 120 mg/kg intraperitoneally) just before angiography. A I
ml syringe fihled with radiopaque contrast medium (iodixanol [Visipaque], 320
Figure 6: Rat inferior vena cava (IVC) stenosis mode! of venous thrornbosis (58).
A severe stenosis was produced in the vein by tying a 5-0 silk suture around the
vena cava to include the prolene suture in the right panel. The prolene was then
pulled out to allow blood to continue to pass up the vein in the Ieft panel.
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mg/mL) and a 26 1/2G needle were used in the femoral vein for injection.
Occlusion was defined as the absence of anterograde blood flow through the
thrombosed venous segment; any antegrade opacification was sufficient to label
the vena cava as recanalized.
111.4 Tissue harvest / Measurement of thrombus size and infrarenal vena
cava weight
The inferior vena cava to the iliac bifurcation was harvested and weighed, and the
weight was normalized to vein length (mglcm) to calculate the mass of thrombus
that formed during the period of venous stasis. This technique is an indirect
measure ofthrombus content but a reliable measure ofthrombus resolution (61).
The samples were then irnmediately snap-ftozen by immersion in Iiquid nitrogen
and store at —80°C until further processing for biochemical study or were fixed
ovemight in Zn-Tris solution (176), dehydrated, and embedded in paraffin using a
routine histological procedure for immunohistochemistry. Each group (n10) of
samples was processed for mRNA extraction (n=4), zymography and western
blottïng (n3), and immunohistochemistry (n3).
The sizes of the thrombi were marked by using the area of thrombus in each
section measured with image analysis software Vision PE, Clemex Technologies
Inc., (Longueuil, QC, Canada). These measurements were expressed in square
millimeters.
111.5 Hïstopathologic and immunohistochemical analysis
C
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Histological and immunohistochemical studies were performed on
paraffin-embedded venous tissue sections. Five-micrometer thick samples were
deparaffinized in xylene and rehydrated in decreasing concentrations of alcohol.
Endogenous peroxidase was quenched by incubation of sections in 0.3% F1202 in
methanol for 15 min. The siides were washed twice with 0.05 molli Tris+IC1,
0.15 mollI NaCI, and 0.03% Tween 20 (TBT) pH 7.4, between each step
throughotit the experiment. Nonspecific binding was biocked by 30-min
incubation with 10% normal goat serum (NGS) or 5% dry miik in TBT (TBB).
lmmunoreactivity was detected for ail primary antibodies iisted in Table 5 by
overnight incubation in TBB in a humidified chamber and revealed by
peroxidase (Vectastain ABC KIT, Vector Laboratories, Burlingame, CA).
Peroxidase activity was detected with 1 mglml diaminobenzidine
tetrahydrochloride (Pierce Biotechnology, Rockford, IL) as chromogen and 0.1%
H20, as substrate. Sections were counterstained with haematoxylin solution
(Vector, Burlingane, ON) and subsequentiy dehydrated in graded ethanol
solutions, cleared in xylene, and mounted in Permount (Fisher Scientific,
Montreai, QC). Slides were visualized with a computerized imaging system
(Vision PE, Clemex Technologies Inc., Longueuii, QC, Canada). Nonspecific
staining was verified by omission ofthe primary antibody or by using nonimmune
normal serum. Perivascuiar coilagen fibrils were detected histoiogically by
Picrosirius red staining (177) and examined by polarized light rnicroscopy.
Collagen volume fractions were evaiuated by analyzing staining intensity per
pixel in multiple fieids mentioned ART Recherches et Technologies Avancees
Inc that only vein wall collagen has been quantified (15—20 fields/section, 2
(J sections/animal, and 3 mice/group
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Antibodies Source Dilution Antigen Specificity
Anti- retrieval
Biotinylated Vector Labs., 1:300 None
GSL-1 Burlingame, Endothelial
CA ceils
-Integrin Chemicon 1:50 10 minutes ai ECs,
«43 95°C in 10 Macrophages,
Clone LM609 mM sodium VSMCs and
citrate (pH Fibroblasts
6.0)
-CD68 Santa Cruz 1:20 10 minutes al
(T-1-2550): Bïotechnology, 95°C in 10 Macrophages
se-9139 Inc. mTvI sodium
citrate (pH
6.0)
-MMP-9 Neomarkers 10 minutes ai Myofibroblasts,
Clone VUC2 Lab vision 95°C EDTA ECs and
Corp lmMpH 8.0 Macrophages
-MMP-2 Neomarkers 1:20 10 minutes al VSMCs, ECs
Clone CA-4001 Lab vision 95°C EDTA and
Corp lmM pH 8.0 Macrophages
-tPA Chemicon
lone GMA-043
-uPA Santa Cruz 1:20 10 minutes aI
(T-I-140): Biotechnology, 95°C in 10
se-14019 Inc. mM sodium
citrate (pH
6.0)
-PAl-1 Santa Cruz 1:100 12 minutes in
(T-1-135): se-$979 Biotechnology, 0.1% Trypsin)
Inc. in TBS ai
room
+nn*narnis ira
Table 5: List of antibodies
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111.5.1 Macrophage content
Paraffin sections of the thrombus taken at 7 and 14 days after surgery from groups
of control mice and diabetic mice (n=3 per group). They were processed for
macrophage immunoreactivity using the monoclonal antibody against the CD 6$
antigen. The percentage area of the thrombus containing the stained CD 6$
antigen (macrophage density) was measured with the image analysis software
described above. In a blinded fashion, positively stained ceils in ten high-power
fields radially around the thrombus were counted and totalled and then indexed to
total thrombus area. The average macrophage density in each group was
calculated.
111.5.2 Neovascular channel quantification
Neovascularization was defined by Griffonia Simplicifolia Lectin 1 (G$L-1) or
Œvf33 positive stained channels. GSL-1 is a biotinylated lectin that identifies ECs
that specifically display Œ-methyl-D-galactopyranosyl groups (17$). The specific
Œvf33 mtegrin represents also a marker of neovascularization as it has been
identified as a cntical modulator of angiogenesis (179).
These channels were counted in the entire thrombus section and totaled. Total
channel counts were then indexed to total thrombus area to account for
differences in section technique, WC sample location, and size of thrombus.
111.6 Western blot analysis
49
Protems were extracted from PiC samples by homogenating with lysis buffer
(1M Tris pH 7, 1M NaC1, lOOmM Sodium Fluoride, 200mM Sodium
ortho-vanadate, NP-40 lOOuIJlOml, 1 tablet of Complete mini, JOOmM PMSF)
and protem concentration determined by the Bradford method (BIO-RAD protem
assay, BIO-RAD). Tissue samples were denaturated and equal amounts of
protein extracts (20 j.tg) were loaded onto a 10% SDS-polyacrylamide gel
accordmg to Laemlli (180). ImmediateÏy afler electrophoresis, the proteins were
transferred to Pure Nitrocellulose Membrane (BIO-RAD Trans-blot Transfer
Medium) in transfer buffer (Tris—glycine, pH 8.3 and 20% methanol). The
mtrocellulose membrane was saturated with 5% skimmed milk powder ni blotting
buffer (0.05M NaPO4 PH 7.4, 0.154M NaCI, 01% Tween 20) for 1 hour at room
temperature. The membranes were washed in TBS-T, and then incubated with
MMP-2 or MMP-9 antibody (1:400 dilution), and uPa and tPa antibody (1: 200
dilution) overnight at 4°C with gentie shaking. Antibody binding was visualized
either with goat anti-mouse or anti-rabbit IgG annbody conjugated to horseradish
peroxidase (Calbiochem, San Diego, Calif) (1:5000) for 90 min at room
temperature. Peroxidase activitv vas revealed by chemiluminescence with
SuperSignal West Pico (Pierce, Rockford, IL). The membranes were exposed to
x-ray film and developed. Quantification of the bands was assessed with
MphaEase software (Alpha Innotech Corporation, San Leandro, CA) and
corrected per ug of protein.
111.7 Zymographic activities
Gelatinolytic activities of MMP-2. MMP-9 were determined by zymographv.
This technique is a modification of SDS-PAGE, based on the incorporation of an
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enzymatic substrate (gelatin) into the electrophoretic gel and the incubation of the
gel in appropnate buffers. It allows visualization of gelatin-degradmg enzymes ai
picogram levels. Electrophoresis of equivalent amounts of total soluble protein
prepared as one part sample with one part Tris-Glycine SDS sample buffer (2X),
was performed under non-reducing conditions in a 7.5% SDS polyacrylamide gel
containing I mg/mL gelatin (Sigma Chemical). The gel vas then washed three
times for 20 min in 2.5% Triton X-100 to remove the sodium dodecylsulfate. The
gel was developed for 18 hours at 370 C in a solution containing 50 mmol/L
Tns-HCL (pH 7.9) and 5 mmoUL CaC12. The solution was removed, and the gel
was stained with coomassie blue and then destained in 10% acetic aci&40%
methanol. MP’W activities were then observed in the gel as light bands against a
dark background. Control zymograms were performed in a similar fashion with
C’ samples known to express both MTVIP-2 and MTvIP-9 (melanoma cell line). Gels
were photographed and densitometric analysis of lysis areas were quantified
using AlphaEase software (Alpha Innotech Corporation, San Leandro, CA).
111.8 RNA isojation and RT-PCR analysis
Aller sacrifice, tissues were subjected to mechanical homogenization in TRIzol
reagent (Molecular Research Center, mc, Cincinnati, Ohio) and combined with
chloroform. $amples were centrifuged, and nucleic acids (RNA) were extracted
from the aqueous layer. The RNA vas subjected to reverse transcription to
produce cDNA. Aliquots of total thrombus RNA (500 ng) were used for first
strand cDNA synthesis in 201.d reaction volume using Superscnpt II reverse
transcriptase (Invitrogen). Aller determining the linear range of RT-PCR for each
of the target genes, amplification of the gene under investigation vas carned out
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using the pnmers summarized in Table 6 amI chosen in two different exons to
distinguish genomic contamination. PCR amplifications were performed with
Platinum Taq DNA polymerase (Invitrogen) accordmg to manufacturer’s
instruction on an Eppendorf Mastercycler gradient usmg following program: step
1, 94°C for 1 mm; step 2, between 52 and 64°C for 1 mm; and step 3, 72°C for 1
min. 40 cycles were performed for the amplification of genes of mterest and 30
cyclers for f3-actm. The amplification for each gene vas in the lïnear curve. PCR
products were visualized on 1.5% agarose gel stained with ethidium bromide and
UV trans-illumination. Quantitative analysis ivas camed out using a
computenzed densitometric imager (ImageQuant; Amersham Biosciences,
Canada) to obtain gene/3-actin ratios. Genes that were studied mcluded
metalloproteinases (MMP-2 and 9), uPa and PAl-1 classically involved in dot
fibnnolysis and thrombus organization and CD14 for monocyteJmacrophage
activity. The list of primer sequences are summerized in Table 6.
Gne Forward primer Reverse primer
M1’4Y-2 5’-CHTGCAGGAGACAAGTTCTGc3-3’ 5’-TTAAGGTGGTGCAGGTATCTGG-3’
MN’W-9 5’-CCATGAGTCCCTGGCAG-3’ 5’-AGTATGGATGHATGATG-3’
CDI 4 5’-GGAAGCCAGAGAACACCATCG-3’ 5’-GCAGGGCTCCGAATAGAATCC-3’
uPa 5’- GGAGAGCTCCTATAATCCTG-3’ 5’-CCAGCTCACAATCCCACTCA-3’
PAT-l 5’-AGGGCTTCATGCCCCACHCTTCA-3’ 5’-AGTAGAGGGCATTCACCAGCACCA-3’
13-actin 5’-CATGGATGACGATATCGCTGCGC-3’ 5’-GCTGTCGCCACGCTCGQTCAGGATC-3’
Table 6: Sequences of pnmers of selected genes for RT-PCR
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ffi.9 Statistical analysis
Descriptive statistics were collected and data reported as mean ± SEM. Graphic
representations were created using Sigma Plot (y 3.5). Statistical analysis vas
performed with Sigma Stat (y 3.5). Mgïographic occlusion rates at different
times were analyzed by fisher s Exact test. for comparison between DM group
and control group, ail data, blood glucose, body weight, thrombus size and
weight, mRNA expression levels and protein levels (western blot and
zymography), were subjected to statistical analysis by a nonparametric
Mann—Whitney test or by two-way analysis of variance (if normally distributed).
for ail statistic tests, a P value ofless than 0.05 was considered signïficant.
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W RESULTS
There was no surgical mortalily in the operatmg process. Deep vein thrombosis,
with or without recanalization, did flot lead to loss of function of limb in any
mouse.
W.1 Successul development of type 2 diabetes in mice
Aduit C57BL16 male mice were fed dunng 10 weeks wïth a high-fat diet to
induce obesity and diabetes. The body weight increased faster (+17.5%) in high
fat-diet fed mice than that in chow-diet fed mice, and reached to the significantÏy
different point by 10 weeks (37.5 ± 2.2 g versus 31.9 ± 2.1 g, n20 in each group,
F< 0.001) and maintained thereafler (figure 7). The same happened to plasma
glucose level, and the significant increase showed in 10 weeks of feeding reached
55.5% (12.6±1.1 mmol/L versus 8.1±0.9 mmol/L, n=20 in each group,P < 0.001),
which indicated the successfiul development of mild type 2 diabetes in these mice
(figure 8).
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Figure 7: Body weight growth in contml and diabetic mice (*P< 0.001 vs
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f W.2 Diabetic mice have Iess thrombus resolution
The 8-day time point of thrombi was chosen from previous studies done by
Wakefield et al. (56), who reported that no outcome measurements revealed any
significant difference between groups at 4 days, consistent with the notion that an
angiogenic response develops later in the course ofthrombus resolution.
Tbrombus resolution was assessed by two separate methods, thrombus area and
thrombus mass.
W.2.1 Thrombus area
At 1 week, the thrombus area was 13.69 ± 0.49 mm2 in control group and 24.23 ±
1.66 mm2 in the diabetic group, which ivas statistically different (P<0.05) (Figure
9). Two weeks afier DVI, a higher sigrnficant difference was also observed
between these two groups (2.6$ ± 1.34 vs 12.41 ± 0.71 P<0.05).
Furthermore, 2 weeks afier the surgery, the thrombus area in both groups became
smaller, especially in the control group, where the reduction was 80% for the
normoglycemic mice, compared to 49% for diabetic mice (P<0.05).
W.2.2 Thrombus mass
As a gross but reliable measure ofthrombus dissolution, djabetic thrombosed WC
weight normalized by length was significantly higher at 1 and 2 week-DVT than
control mice (Figure 10). At these time points, the increase was 85% and 56%
respectively (P<0.05). $imilarly as in thrombus area, the decrease in thrombus
weight 2 weeks afier surgeiy was statistically significant in the 2 groups and more
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important in the control (40%) than diabetic group (18%) reflecting a lesser
abjlity of diet-induced type 2 diabetic mice to resolve venous thrombi.
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Figure 9: Thrombus areas in control and diabetic groups at 1 week or 2
weeks after surgery. Thrombus area in the diabetic group was greater than in the
control group with 1 .$-fold and 4.6-fold increase at 1 and 2 weeb respectively.
At 2 weeks, there was a significant decrease in both groups, which was more
conspicuous in the control group (80% vs 49% in diabetic mice) (*P< 0.05
compared with respective control; # P <0.05 compared within control mice $ P <
0.05 compared within diabetic mice, n=3).
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Figure 10: Thrombosed IVC mass/Iength in control and diabetic groups at 1
week or 2 weeks after surgeiy. There ivas a statistically signfficant difference
between control and diabetic group at both 1 week and 2 weeb after surgery.
(*p< 0.05 compared with respective control; # P < 0.05 compared within control
mice $ p <0.05 compared within diabetic mice, n=3).
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IV.3 Thrombus recanalization is impaired in diabetic mice
To determine whether diabetes would impair natural thrombus recanalization,
angiography analysis of thrombus blood flow and immunohistological methods
were used.
IV.3.1 Angiography
Mgiography analysis enables detection of in vivo mtra ami perithrombus blood
flow through thin plane in the thrombosed INC, ami is used in a similar manner to
that described for models of experimental intracranial aneurysms elaborated in
our laboratory (73). Restoration of blood flow afler WC ligation was scored O for
occluded veins and 1 for recanalized, as shown in figure 11 with representative
angiographies. Both 1 week-control and 1 week-diabetic mice presented with
occluded WC. Two week-control mice showed blood flow through side
collaterals and within the thrombus body, whereas blood flow in 2-week diabetic
mice vas mainly via side collaterals.
As shown in Table 7, at 1 week after the surgely, 80% (8/10) mice in control
group occurred complete fliC occlusion, meanwhile 90% (9/10) mice in diabetic
group did. No significant differences in flow restoration between them.
At 2 weeks afler the surgeiy, ii was documented in 90% (9/10) of control mice,
meanwhile it was efficient in 10% (1/10) ofdiabetic mice (P0.001, n=10).
C
60
1 week
2 weeks
Figure 11: Angiograms in control and diabetic groups at 1 week or 2 weeks.
A and B show two representative mice which presented with complete IVC
occlusion at 1 week. C shows thrombus recanalization in control group at 2 weeb.
D reveals maintained complete WC occlusion in the diabetïc group at 2 weeks
(The venous blood recirculated through by-pass vein).
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Time Group Amount Recanalization
Yes No Rate
Control 10 2 $ 20%
DM 10 1 9 10%
Control 10 9 1 90%
DM 10 1 9 10%
Tabte 7: Angiography scores in control and diabetic groups
W.3.2 Histologicat and immunohistotogical analysïs of neovascutar
channels
In many studies, thrombus neovascularization identified by histological and
immunohistoligical methods confirmed that channels communicate with the
systemic circulation (56, 61). In the current study, thrombus neovascularization
was assessed by immunohistochemistry and was estimated by counting G$L-1 or
aV3 mtegrin-positive channels. The correlation between avf33 positive channels
and GSL-lstaining is essentially identical (data not shown). As shown in Figure
12a and b in both control and diabetic mice, recanalizing channels were
identified as spaces, lined by flat GSL-1 positive endothelial-like ceils. These
channels were identical in morphology and develop in the penphery of the
thrombus as part of the normal course of resolution but varied in proportion
between the two groups. Fewer channels were present in 2 weeks of diabetic mice
thrombi as compared with controls despite an important immunostaining in the
margin of the thrombus (Figure 12d). Some GSL- 1 positive celis were also
oo
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detected mvading the thrombus. In the 2 week-control mice, thrombus had been
reduced to a longitudinal. endothelialized subintimat streak (arrow in Figure
12c).
Consistent with these observations was channel quantification (Figure 13). At 1
week after DVT, there was no difference in the number of neovascular channels
between control and diabetic mice. Control mice had 6.3 ± 0.3 channels/thrombus
area (mm2) and diabetic mice had a similar number of channels (5.6 ± 0.4
channels/thrombus area (mm2). 0f note, 2 week-diet induced type 2 diabetic mice
had 3-fold fewer GSL-1 positive channels compared with controls (n3; f<0.05).
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Figure 13: Quantification of thrombus neovascular channels by positive
GSL-1 stmning. No significant difference was observed between the number of
channels in diabetic and control mice thrombi at 1 week afler surgery. Note
significantly fewer channels in 2 week-diabetic thrombi as compared with
controls. (*p< 0.05 compared with respective control: # P < 0.05 compared
within control mice $ P <005 compared within diabetic mice, n=3).
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IV.4 Diabetic mice have a higher inflammatory response
IV.4.1 Expression of CD14 mRNA
Thrombus macrophage content was investigated by CD14 mRNA experession at
surface of macrophages. As compared with control mice, the expression of CD 14
mRNA was upregulated in diabetic mice. This difference was statistically
significant in I and 2-week-old thrombi with a 1.3 fold (F<O.05) and 9 fold
(P<O.05) increase respectively. Interestingly, CDI4 mRNA expression decreased
by 7 fold at 2 weeks in control group (P<O.0001), while contrarily it showed a
higher increase at 2 weeks in diabetic group. However, the difference of CDI4
( mRNA expression level between 1 and 2 weeks in diabetic group did flot reach
significance; due to the high variability ofthe values (Figure 14).
IV.4.2 Immunohistochemical staining of CD68
The inflammatory response in each thrombus cross-section was investigated by
an immunohistochemical technique using a monoclonal CD62 antibody to
identify macrophages. At I week post-ligation, venous thrombi in diet-induced
type 2 diabetic animals exhibited more CD68 positive cells (Figure 15b) than
normoglycemic mice (Figure 15a). At this time point, the macrophages were
mainly found within the periphery of the thrombus in both control and diabetic
mice. In contrast, in 2-week-old venous thrombi, the distribution was different in
diabetic mice (Figure 15d); macrophage recruitment invaded the totality of the
thrombus and the staining was significantly enhanced. No apparent macrophage
66
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infiltration was obsenïed in 2-week-old venous thrombi of control mice winch
were ail without any significant staining (Figure 15c).
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Figure 14: CD14 mRNA expression in control and diabetic mice. At I week,
CD14 mRNA was upregulated in diabetic group compared to control group
(0.977 ± 0.0741 vs 0.745 ± 0.02$). At 2 weeks, CD14 mRNA was continuously
upregulated in diabetic group (0.977 ± 0.0741 vs 1.217 ± 0.405), while it was
downregulated in control group (0.745 ± 0.028 vs 0.105 ± 0.065). (*P<0.05
compared with respective control; # P < 0.05 compared within control mice n=3).
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infiltration was observed in 2-week-old venous thrombi of control mice which
were ail without any significant staining (Figure 15c).
The quantification of the inflammatory response in diet-induced type 2 diabetes
mice as seen in Figure 16, showed approximately a two fold increase at I week
as compared to control animais (F<O.O I). At 2 week-post ligation, intrathrombus
macrophages in diabetic sections were 35 times greater than in controi sections
(P<O.00 1).
Moreover, thrombus macrophage content decreased significantly as the thrombus
ages between 1 and 2 weeks in control mice (six-fold tesser, P<O.O1); while it
ampiifïed in 2-week-diabetic mice within the same period (three fold greater than
one-week-diabetic mice, P<O.O I).
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Figure 16: Thrombus macrophage content in control and diabetic mice at 1
or 2 weeks after IVC ligation. By image analysis, the percentage of CD68
stained ceils per thrombus size area was evaluated for three mice in each group.
(*p<o.os compared with respective control; #P<O.05 compared within control
mice $ P<O.05 compared within diabetic mice, n3).
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IV.5 Vein wali fibrosis was elevated in diabetic mice
To assess if the altered DVT resolution in the diabetic mice affected the normal
thrombus fibrotic process, histochemical staining for total collagen ivas
investigated. Picrosinus red staining showed the intensity of fibrosis to be
concentrated in the thrombus penpheiy and in the vein wall at 1 -week time point
in both control and diabetic mice (Figure 17a and 17b).
At 2 weeks, a strong staining was documented in both groups (Figure 17c and
17d). Collagen level quantification of the vein wall was reported in Figure 18,
and indicated at 1 week-post DVT, two-fold less collagen deposition in diabetic
mice than control mice. While the fibrotic response showed a trend toward an
increase in diabetic mice at two weeks, this difference did not reach statistical
(Z significance. Both groups showed an increase in collagen deposition between 1
and 2 weeb afier surgery. However, the increase in control mice was 25.7%
whereas it vas 183% in the diet fat-feU mice, reflecting higher alteration in the
vein wall remodelling.
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Figure 18: Collagen quantification of the velu waJI in control and diabetic
mice at 1 or 2 weeks. Data are derived from quantification of the mtensit of
staining per pixel in each IVC section and represent the mean of 15-20 fields per
section, two sections per mouse, n=3 per group. (*P< 0.05 compared with
respective control and $P < 0.05 compared within dïabetic mice, n=3).
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IV.6 The fibrinolytic system was altered in diahetic mice
As other investigators have shown, the fibrinolytic system is probably the primwy
mechanism for DVT resolution (83, 181, 182). Gene expression was analyzed and
detection of protein expression vas perfonned for plasminogen activators uPA
and tPA, and for their main inhibitor PAl-1.
IV.6.1 uPa and PAl-1 mRNA levels
uPA mRNA levels trended to lesser expression in diabetic mice at 1 week (-21%)
and 2 weeks (-12%) afier thrombus induction, but these decreases did flot reach
statistical significance (Figure 19). However. analysis of the thrombosed WC
homogenate showed a significant downregulation in uPA gene expression
between 1 and 2 weeks in both groups (-57%, P = 0.013 in control group and
—52% P = 0.02 1 in diabetic group).
PAl-1 and uPA mRNA expressions trend in opposite directions in the thrombosed
IVC during DVT resolution. One week aller WC lïgation, mRNA levels of PAl-1
increased in diabetic mice by 20% (Figure 20). Although tins did flot reach
statistical significance, the up-regulation was greatest (+55%) in 2-week-old
thrombosed WC (control mice 0.74 ± 0.06 vs diabetic mice 1.15 ± 0.02, P =
0.002, n=4).
As thrombus ages and resolves, gene expression of PAl-1 vas less downregulated
in diabetic mice (-14%, P = 0.023) than in control mice (-34%. p = 0.061)
reflecting less fibnnolytic activity leading to reduced thrombus resolution with
diet-induced type 2 diabejes.
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Figure 19: Expression of uPa mRNA in control and dïabetic mice. uPA
mRNA levels normalized with -actm mRNA levels showed a twofold decrease
at 1 and 2 week afler surgery in both control and diabetic mice. (#P<0.05
compared within control mice $P <0.05 compared within diabetic mice. n=4).
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Figure 20: Expression of PAl-1 mRNA in control and diabetic mice. PAl-1
mRNA expression showed higher levels in diabetic IVC/thrombus samples than
in controls. A significant downregulation followed as the thrombus matured in
both groups (-14% vs -34%) (*P<O.05: compared with respective control;
#P<O.05 compared within control mice and $P<O.05 compared within diabetic
mice, n4),
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W.6.2 Expression ofuPa, tPa and PAl-1 pmtein (Western blot analysis)
At 1 week, there vas no sigrnficant difference of uPa protem expression between
control and diabetic groups (F=O 098) (Figure 21). At 2 weeks, uPa protem
expression was down-regulated compared to control (18% less than control
P=0.0098). In both groups, uPa expression was decreased with time by 30% at 2
weeks when compared to 1 week P<0.05).
The expression of tPa in diabetic mice vas down-regulated compared to the
control either at 1 week (P=0.0269) or at 2 weeks (P=OE0369). The tPa level at 2
weeks was lower than that at 1 week in both control and diabetic groups but this
decrease did not reach statistical significance (Figure 22).
In contrast, the expression of PAl- 1 protein was up-regulated in diabetic mice
compared to the control either at 1 week (P=0.0033) or at 2 weeb (P0.0466).
However, as the thrombus ages, there was no sigrnficant difference between the
PAl-1 level at 1 week or at 2 weeks in diabetic group (Figure 23)
$erial thrombosed WC sections from control and diabetic mice were
immunostained with an antibody against uPa and PAl-1 (Figure 24). In organized
thrombus, uPa and PAl-1 were mainly found in the ingrowing subendothelium.
uPa was accumulated in the subendothelium under microthrombi and was
strongly positive in control group at E week (Figure 24a) and 2 weeks (Figure
24c), as compared with DM group (Figure 24b and 24d). PAl-1 was slightly
stronger positive in DM group at 1, 2 weeb, as compared with control group..
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Figure 21: Western blot analysis of uPa in control and diabetic protein
extracts. At 2 weeb. uPa protem expression in diabetic mice vas statistically
different from control group. (‘‘P< 0.05 compared with respective control,
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Figure ZZ: Western blot analysis of tPa in protein extracts of control and
diabetic mice. The expression of tPa in diabetic mice was down-regulated
compared to the control either at I week (-19% P=OE0269) or at 2 weeks (-21%
P=O 0369). (*P<0.05: vs control; n3).
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Figure 23: Western biot ana]ysis of PAl-1 in protein extracts of contro] and
diabetic mfce. The level ofPM-I protein expression is 1.5 and 1.2-fold higher in
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W.7 The M11P system is enhanced in Diabetic mice followed by a
decreased synthesis and activity
W.7.1 Expression of MMP-2 and MMP-9 mRNA
Compared to the control mice, the MMP-2 mRNA levels of diabetic mice were
up-regulated at 1 week (P=O01 8) but down-regulated at 2 weeks (P0.002)
(Figure 25). The mRNA level vas increased at 2 weeks in the control group
(f=0.0014), and decreased in the diabetic group (P0.0021).
The MMP-9 mRNA expression of diabetic mice vas up-regulated at 1 week
(2.36-fold increase compared to control group, P = 0.02$) (Figure 26), whiÏe
decreased to the control level at 2 weeks. The difference between the mRNA
level at 2 weeb and at 1 week in diabetic mice vas statisticatly significant (P
0.013), whereas the control group showed an upregulation of MMP-9 mRNA
level by 2 weeks afler IVC ligation.
IV.7.2 Gelatinoiytic activities of MMP-2 and M1IP-9
1 week- MMP-2 total gelatinolytic activity in diabetic mice was 1 .7-fold greater
than in control mice (P<0.05) and became 1.2-fold increased by 2 weeks (P<0.05)
(Figure 27). As thrombus matured, MMP-2 activity decreased by 20% in diabetic
mice contraly to control mice where the MMP-2 activity augmented by 12.5%
(P<OE05). Simitarly, MMP-9 activity was greater in diabetic thrombi 1 .5-fold at 1
week and 1 .3-fold at 2 weeks as compared with controls (P<0.05). However the
decrease by 2 weeb was not statistically significant in diabetic mice.
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W.7.3 Expression of MMP-2, MMP-9 proteïn
Densitometnc analysis ofMMP-2 and MMP-9 levels by Western immunoblotting
showed sïgnificantly increased levels in the thrombosed vein homogenate at 1 and
2 weeks in diabetic mice as compared with controls (Figure 28 and 29).
Two-fold greater protein level of MMP-2 and 1.7 fold greater protem level of
MMP-9 were present in the diabetic ligated vein at 1 week, as compared with
control thrombi (P<O.05). By 2 weeks, less MMP-2 (-30%) and MMP-9 (-18%)
activities were present in the diabetic groups (P<O.05) although, stili remaining
more elevated than controls groups.
Thrombosed WC sections ftom control and diabetic mice were immunostained
with an antibody against MIVW-2 and MMP-9 (Figure 30). Staining was present
C in both the vein wall and cellular components of the thrombus. Both at 1 week
and 2 week-DVT, the diabetic mice showed more IvflvW-2 and MMP-9 staining
compared to control mice. Two weeks afier surgeiy, the immunoreactivity of both
MMP-2 and MMP-9 in diabetic mice was less pronounced as compared to the
immunostaining 1 week afler DVT.
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Figure 25: Expression of MMP-2 mRNA in control and diabetic mice.
Diabetic mice showed an upregulation of MMP-2 mRNA levels by 1 week
whereas, a dowegu1ation occuned by 2 weeks after thrombus induction (*P<O.05:
vs control; $P<O.05: vs 1-week diabetic mice, #P<O.05: vs 1-week control mice,
n=3).
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figure 26: Expression of MMP-9 mRNA in control and diabetic mice. M
upregulation of MMP-9 mRNA level was detected by L week afier PiC ligation
followed by a downregulation by 2 weeks in diabetic mice, in opposite, control
group showed a higher level by 2 weeks. (*P<O.05: vs control; $P<O.05: vs
1-week diabetic mice, # P<O.05: vs 1-week control mice, n=3).
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C V. DISCUSSION
In the first part of the thesis, molecular and cellular mechanisms associated with
venous thrombus organization and resolution in normoglycemic mice and those
related to the artenal complications of type 2 diabetes were reviewed. However,
arterial and venous thromboses are separate pathological disorders, different in
their pathology, pathophysiology, epidemiology and treatments. Arterial
thrombosis could be considered as a chronic disease related to a slowly increasing
severity of atherosclerosis, although its symptoms are usually acute due to
blocking of the vital blood flow to an organ. In contrast, venous thrombosis is an
acute disorder with chronic symptoms and occurs from a sudden dot. Arterial and
venons thrombosis share and differ vastly in some etiologies. For example, the
atherogenic factors for arterial thrombosis such as smoking, hypertension and
hyperlipidemia do flot appear to affect the nsk of venous thrombosis (183).
Therefore, the current smdy associates these two pathologies. DVT and
diet-induced type 2 diabetes, to determine whether there is an adverse hemostatic
impact of type 2 diabetes on the formation and resolution of DVT in mice.
In addition to promoting obesity, high-fat diets have been associated with an
increased risk for developing type 2 DM in epidemiological studies, and notably
this association has been found independent of obesity (43).
Several murine models of type 2 diabetes to study vascular complications have
been reported. One animal model that is particularly susceptible to the effects of
dietary fat is the C57BLI6J (B6) mouse. This animal will develop severe obesity,
hyperglycemia, hyperinsulinemia, insulin resistance and endothelial dysfiinction
C’ (36) when weaned to high-fat diets, but will remain lean and euglycemic if the fat
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cE’ content ofthe diet is limited (184). As a model of type 2 diabetes, B6 mice seem to
closely resemble common forms of the human disease in that they will on!y
manifest the disease afier developing obesity and in which the disease results ftom
the interaction between environmental factors and genetic predisposition.
Animal models of stasis-induced DVT after ligation ofthe inferior vena cava (IVC)
have been widely used to investigate the mechanisms responsible for thrombus
resolution (61, 131 and 181). Our mouse mode! design is inspired by combination
ofreduced flow and endothelia! disturbance, two components ofVirchow’s Triad.
The venous thrombi produced in this mode! have a laminar structure and were
morpho!ogically sirnilar to human thrombi (56, 61).
A!though type 2 diabetes has been long demonstrated as a high risk factor of
thrombosis, to the author’s knowledge, no study has shown its ro!e in the
formation and evolution ofthe deep vein thrombus (DVT).
DVT reso!ution invo!ves dissolution of the thrombus matrix by fibrinolysis,
cel!u!ar influx and neovascularization. Our current data (resu!ts of western blot
were normalized by per ug of protein) show that a!l these parameters are affected
in diabetic mice, revea!ing that DVT reso!ution is impaired and might suggest
that the metabolic disorders, such hypergtycemia, insulin resistance, dystipidemia
and advanced glycation end product might be implicated in the pathogenesis of
DVT.
The data herein support several mechanisms associated with type 2 diabetes that
may direct!y affect thrombus resolution. f ive interre!ated conclusions can be
drawn from the data where diet induced type 2 diabetes is associated with: 1)
decreased venous thrombus reso!ution and neovascu!arization; 2) a higher
Ç inflammato response in the thrombosed IVC, 3) a more pronounced vein wal!
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remodeling; 4) an altered fibrinolytic balance with a trend towards an
antifibrinolytic state; and 5) an upregulation followed by a dowregulation in the
expression profile of the MMP system. These findings may present plausible
molecular mechanisms for impaired venous thrombi resolution which could
contribute to more risk of post-phlebitic syndrome in type 2 diabetes.
V.1 Type 2 diabetes decreases the resolution and recanalization ofDVT
Venous thrombi resolution and recanatization involves thrombus retraction and
neovascularization. Retraction resuits in the formation ofcell-lined clefts between
the body of the thrombus and intima of the vein wall. This is combined with new
vascular channels within the thrombus as a resuit of endothelial ceil proliferation
and migration. Therefore similar to angiogenesis, thrornbus recanalization is
affected by the same mechanisms that regulate new vessel formation.
Our diet-induced diabetic mice showed a significant reduction in venous thrombi
resolution and recanalization as evidenced by a larger thrombus size and content,
by unfavorable angiographic evolution and, by a reduced number of neovascular
channels identified and quantified through the use ofimmunohistochemistry.
Diabetes is associated with abnormal angiogenesis. The insufficient angiogenesis
contributes to impaired wound healing, and impaired new vessel growth
development (185). Diabetes-induced impairment of collateral formation bas
been demonstrated in animal models. Hindlimb ischemia created by ligation of
the femoral artery is associated with a reduced formation of capillaries and a
reduction in blood flow to the ischemic Iimb in diabetic (NOD) versus
C” non-diabetic (C57) mice (186). A possible mechanism by which diabetics are
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affected in their ability to forms collaterals was reported by the study of Tepper et
al., which suggests that type 2 diabetes may alter circulating endothelial
progenitor celis (EPCs) biology exhibiting impaired proliferation, adhesion and
incorporation into vascular structures. Interestingly, EPCs are recruited into
venous thrombi and may play an important part in the resolution ofthrombi (71).
These findings may suggest a similar alteration in EPC functions during DVT
resolution in diabetic mice.
In addition, the abnormal metabolic state of type 2 diabetes increases adhesion of
platelets and monocytes and resuits in abnormal fibrinolysis and
hypercoagulation. Activated platelets interact with the endothelium and promote
adhesion ofplatetets to monocytes. Circulating platelet-monocyte aggregates may
release procoagulant, oxidative and mitogenic factors (24). The equilibrium
between endogenous tissue plasminogen activator and PAl-1 is altered. AIl these
significantly contribute to the inflammatory and procoagulant response in
diabetes.
V.2 Type 2 diabetes increased inflammatory response in DVT
Diabetes associated vascular disease affects multiple vascular beds. There is a
significant inflammatory component with activation of the transcription factors
such as nuclear factor-iB and activator protein I, increased endotheliat and
leukocyte expression of adhesion molecules and release of chemokines that
aftract monocytes and inflammatory cytokines such as IL-1, TNf-Œ (187).
The interrelation between venous thrombosis and inflammation has been well
C characterized. Previous studies have shown that monocytes are recruited in large
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numbers into maturing human and experimental venous thrombi (62). Moreover,
a role for the thrombus in directing the inflammatory reaction has been suggested
and thrombus resolution did flot occur if their recruitment is restricted (60-62).
Our data showed markedly upregulated CDI4 gene expression in thrombosed
IVC ftom diabetic mice and intense macrophage invasion initially around
thrombus edge which became entirely distributed within the thrombus. This
temporal and spatial pattem of monocyte movement was reported previously in
non diabetic mice by McGuinness et al. (15 1).
The concept that a proinflammatory environment is crucial for venous thrombi
resolution has been documented in many laboratories (128, 164). it is possible as it
bas been shown in normoglycemic mice, that monocytes/macrophages orchestrate
thrombus resolution by producing a variety of cytokines, chemotactic factors,
angiogenic factors, proteases and their inhibitors that regulate celi migration, ECM
turnover and revascularisation. However, in diabetic mice this increasing
macrophage recruitment into the thrombus did flot improve its resolution. It is
likely that once monocytes convert to macrophage phenotype in the thrombus,
their fibrinolytic activity decreases (down-regulation of uPA/tPA and
up-regulation of PAl-1) which will impair lysis ofthrombus ftom within.
Thus, it is reasonable to speculate that a mechanism which is macrophage
dependent may contribute to altered DVT resolution in diabetic mice and these
inflammatory ceils may be prothrombotic as shown in many circumstances via
the production of tissue factor (188), PAl-1 (189) and thrombin activation (190).
(J V.3 Type 2 diabetes elevates the vein wall fibrosis in DVT
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ECM displays a very dynamic equilibrium with constant synthesis, degradation
and reorganization. Vascular ECM proteins such as coliagen 1 and 3, fibronectin
and thrombospondins flot oniy function as scaffolding proteins but are aiso
invoived in matrix signalïng by ÎnteractÏng with the integrin family of protein and
trigger growth-promoting signais (191).
Many studies have provided evidence for diabetes—induced aiteration in ECM
turnover and reguiation. There is a particular impact on the ECM component, the
basement membrane whose thickening is an ultrastructurai haiimark in diabetic
patients (192). In veins from human diabetic patients and an experimentai
diabetic animal model, patches of thickening were observed and could be reiated
to endotheiiai ceil dysfunction (19).
Prior study has suggested that a late fibrosis that occurs in vein wails after the
development of a DVI is the resuit of a loss of the dynamic equilibrium. This
involves the progression of vein walls ftom normaily thin and compiiant to a
relativeiy thick and fibriotic state, with the deposition and accumulation of
coiiagen and the loss of normal vessel ECM (194). In this study, afler
two-week-DVT, the elevated vein wali fibrosis was found in both control and
DM; however, the increase coliagen deposition in diabetic mice within I and 2W,
is by far more important than in CM, which indicated a higher aiteration in the
vein wall remodeling. Thus it is iikely that type 2 diabetes contribute to vein wall
damage with further enhancement of thrombus collagen deposition, which
thickens the venous waii. This is known to compromise valvuiar function and
leads to post thrombotic venous insufficiency (193).
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G) V.4 Type 2 diabetes alters the fibrinolytic and MMPs system in DVT
fibrinolytic systemic activity is known to be diminished in diabetic and
insulin-resistant human subjects, which might be attributable to several
mechanisms, including PAl-1 production (16). Hyperglycemia directly or
indirectly (eg, via oxidative stress or advanced glycation products) increases
MMP expression and activity (194).
DVT resolution is known to be an inflammatory process and involves fibrinolytic
and MMP systems through a series of cellular and molecular events. Previous
studies have shown that the activities of the fibrinolytic system are altered and
those of MMPs (MMP-2, MMP-9) are markedly increased (60, 95) after
formation ofvenous thrombi.
V.4.1 Type 2 diabetes inhibits the fibrinolytic system
Prior experimental studies suggest the abnormality of the fibrinolytic system is
one of the major etiologic factors in DVT (195, 196). The plasmin system, by
activation of uPA, is a primary mechanism of venous thrombolysis (164).
Urokinase, with its dominant role in ceil invasion, is thought to be an important
mediator of pericellular proteolysis, whereas, tPA is responsible for the
dissolution of fibrin from the vascular tree. Both are inhibited by PAl-1. In
normoglycemic conditions, fibrinolytic activity is enhanced by upregulation of
expression and activities of uPA and tPA after DVT (95, 197), but is impaired in
arterial vessels in type 2 diabetes (7, 198).
o
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Our data show that diet-induced type 2 diabetic mice is associated with a decrease
in uPA and tPA expressions and an increase in their PAl-1 expression at the gene
and protein levels in the thrombosed IVC. These variations demonstrate an
alteration in the fibrinolytic state in the venous bed with a trend towards an
anti-fibrinolytic state. Increased PAl- t production and reduced uPA and tPA
levels seemed to be an important contributor to the development of venous
thrombosis and the failure of resolution and recanalization in diabetic mice as
evidenced from impaired venous thrombus resolution in uPA-/- knockout mice
(164).
In addition to fibrin degradation, the fibrinolytic system also plays a role in other
biological processes including angiogenesis. One of the functions of plasmin in
the vascular wall is the activation ofMMPs.
V.4.2 Type 2 diabetes enhances MMPs system
The MMP family is essential for ceil migration, matrix remodeling, and
angiogenesis. Their proteolytic activity must be precisely regulated by TIMPs
through complexes of the catalytic MMP domains with various TIMPs (7, 104).
In concert, MMPs are abte to degrade a wide spectrum of matrix proteins and
therefore, they are considered to be the primary class of proteases involved in
degradation of the endothelial basement membrane and interstitiat matrix
degradation. Quiescent ECs produce littie or no MvIPs, whereas the expression of
several MMPs is strongly up-regulated in activated ECs in vitro and in
endothelium ofvessels in wound healing, inflammation and tumors (199). MMPs
stimulate angiogenesis primarly by matrix degradation and also may include the
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activation of growth factors and cytokines, the recruitment of EPCs and the
degradation of inhibitors.
In Type 2 diabetes, it is well documented that gene expression and activity of
MMPs are altered in arterial vessel wall. However, there are stili controversies
regarding the effects of type 2 diabetes on vascular MMPs. These changes resutt
in an imbalance in vascular matrix homeostasis and contribute to damage of a
gel-like form and scaffolding structure. Some of studies have shown increased
mRNA levels and activity of MMPs, independent of the presence or absence of
tPA or uPA in type 2 diabetes (191, 200).
The expression of the principal collagenases (MMP-2 and MIvIP-9) is increased
in the DVT model (7, 57, 60). Circumstantial evidence has suggested an
(Ej important role of MMPs systems in molecular pathway involved in the resolution
ofthe thrombus (7, 57).
Our data showed that mRNA expression and activity of MMP-2 and MMP-9
signiflcantly increased at 1 and 2 week-post DVT compared to normoglycemic
mice. However, their expression was decreased at 2 weeks, after formation of
DVT in type 2 diabetic mice. These resuits may suggest that gene expression of
MMP-2 and MMP-9 were stimulated by type 2 diabetes and formation of DVT,
but stimulation of type 2 diabetes dominated in late resolution of thrombus and
revealed time-dependent differential regulation ofMMPs (60, 105, 109). Our data
are in agreement with resuits of the arterial vasculature reported by Portik-Dobos
and colleagues (201). They showed that changes in MMP synthesis and activity
might be time dependent and speculate that in the early phase of diabetes, the
9$
MMP system may be upregulated to allow the vascutar ceils to migrate and
contribute to intimai hyperpiasia. Kowever, with the progression of diabetes, the
MMP system is suppressed, causing ECM deposition and fibrosis.
In addition, the pathogenesis of impaired angiogenesis in diabetes may be
explained by an up-regulation of MMP-2 and MÎVIP-9 resuiting in an increased
formation of potent angiogenic factor such as tumstatin and angiostatin generated
by theses proteases through proteolytic cleavage of plasminogen as reported by
Chug et al., 2006 (202) in the arterial vasculature. Furtheremore, in our study the
downregulation ofMMP-2 and MMP-9 at 2-weeks was correlated with increased
collagen deposition suggesting impaired collagenolysis.
DVT formation and Type 2 diabetes coutd increase activities of MMP-2 and
MMP-9 respectively. Their increased activities observed in diabetic venous
thrombi are probably the combinations ofthe effects ofthe two pathologies.
o
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C V.5 CONCLUSIONS
Using a deep venous thrombosis model in diabetic mice, this study demonstrated
a higher risk of thrombosis and less thrombus resolution in the diabetic
environment as ïllustrated by higher thrombus weight and size, and decreased
recanalization. An increase of late macrophage infiltration to the thrombosis site
under the diabetic condition may contnbute to the increased fibrosis during the
thrombosis pathogenesis. The upregulated PAl-1, and downregulated uPA and
tPA protein level in diabetic DVT mice may contnbute to the higher nsk of
thrombosis. Interestingly, the upregulation followed by a downregulation of
MMP-2 and MMP-9 is associated with the increase of thrombosis in diabetic
mice which may be explained by the in situ abnormal degradation of ECM
induced by MMPs followed by the exposure of thrombogenic tissue to the
penpheral blood in hypercoagulatic condition.
It is likely that type 2 diabetes amplified the nsk of venous thrombosis and flirther
impaired its resolution through a higher inflammatory response and alteration of
the fibnnolytic and MMP systems. However, it would be necessary to confirm
these resuits in other expenmental models of type 2 diabetes.
finally, this study may suggest that thromboembolic arterial diseases share some
similarities with venous thrombosis.
Alteration of endogenous fibrinolytic balance through modulation of PAT-1, uPA,
and tPA might be a useful therapeutic target for the prevention of thrombosis in
diabetic patients.
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